adamantane has been researched along with vildagliptin in 548 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 154 (28.10) | 29.6817 |
| 2010's | 381 (69.53) | 24.3611 |
| 2020's | 13 (2.37) | 2.80 |
| Authors | Studies |
|---|---|
| Deacon, CF; Dunning, BE; Foley, JE; He, YL; Holst, JJ; Ligueros-Saylan, M; Mari, A; Sallas, WM; Watson, C | 1 |
| Brandt, I; Chen, X; De Meester, I; Joossens, J; Lambeir, AM; Maes, MB; Scharpé, S | 1 |
| Balkan, B; Bolognese, L; Burkey, BF; Hughes, TE; Li, X; Mone, M; Russell, M; Wang, PR | 1 |
| Ahrén, B; Foley, JE; Pacini, G; Schweizer, A | 1 |
| Erlich, R | 1 |
| Ahrén, B; Burkey, B; Hughes, TE; Sörhede Winzell, M | 1 |
| Byiers, S; Foley, J; Holmes, D; Ristic, S | 1 |
| Edelman, SV | 1 |
| Brandt, I; De Meester, I; Ketelslegers, JM; Lambeir, AM; Scharpé, S; Vanderheyden, M | 1 |
| Lebovitz, H | 1 |
| Ahrén, B | 7 |
| Heinzl, S | 1 |
| Dunning, BE; Foley, JE; Mänttäri, S; Matikainen, N; Mills, D; Schweizer, A; Taskinen, MR; Ulvestad, A | 1 |
| Galbreath, E; Holmes, D; Jauffret-Kamel, S; Pratley, RE | 1 |
| Jago, C | 1 |
| Bates, PC; Ristic, S | 1 |
| Inoue, T; Kira, K; Nagakura, T; Saeki, T; Shinoda, M; Tanaka, I; Yamazaki, K; Yasuda, N | 1 |
| Barnett, A | 1 |
| Choukem, SP; Gautier, JF | 1 |
| Drucker, DJ; Nauck, MA | 1 |
| Henness, S; Keam, SJ | 1 |
| Bailey, CJ; Flatt, PR; Green, BD | 2 |
| Golozoubova, V; Gotfredsen, CF; Knudsen, LB; Raun, K; Rolin, B; von Voss, P | 1 |
| Foley, JE; He, YL; Horowitz, A; Ligueros-Saylan, M; Sallas, W; Watson, CE | 1 |
| Chang, CN; Chao, YS; Chen, CT; Chen, X; Cheng, JH; Chien, CH; Coumar, MS; Han, CH; Hsieh, HP; Hsu, LJ; Hsu, T; Huang, YW; Jiaang, WT; Tsai, TY; Wu, HY; Wu, SH | 1 |
| Mikhail, N | 3 |
| Dejager, S; Mills, D; Pi-Sunyer, FX; Schweizer, A | 1 |
| Baig, MR; Balas, B; Cusi, K; Darland, C; Deacon, CF; DeFronzo, RA; Dunning, BE; Foley, JE; He, YL; Holst, JJ; Ligueros-Saylan, M; Mari, A; Wang, Y; Watson, C | 1 |
| Biollaz, J; Buclin, T; Grouzmann, E | 1 |
| Baron, MA; Dejager, S; Mills, D; Rosenstock, J; Schweizer, A | 1 |
| Bosi, E; Camisasca, RP; Collober, C; Garber, AJ; Rochotte, E | 1 |
| Augustyns, K; Brandt, I; Chen, X; Cheng, JD; De Meester, I; Dubois, V; Lambeir, AM; Maes, MB; Scharpé, S; Van der Veken, P | 1 |
| Baron, MA; Dejager, S; Garber, AJ; Rochotte, E; Schweizer, A | 1 |
| Baron, MA; Camisasca, RP; Couturier, A; Cressier, F; Dejager, S; Kim, SW; Rosenstock, J | 1 |
| Dejager, S; Foley, JE; Razac, S; Schweizer, A | 1 |
| Winkler, G | 1 |
| Albrecht, D; Baron, MA; Chang, I; Dejager, S; Fonseca, V; Schweizer, A | 1 |
| Pratley, RE; Salsali, A | 1 |
| Bullock, JM; Deacon, CF; Dunning, BE; Foley, JE; He, YL; Holst, JJ; Ligueros-Saylan, M; Wang, Y | 1 |
| Helms, K; Kleppinger, EL | 1 |
| Ahrén, B; Burkey, B; Hughes, TE; Sundler, F; Wierup, N; Winzell, MS | 1 |
| Campestrini, J; Dilzer, SC; Dole, WP; He, YL; Howard, D; Lasseter, KC; Ligueros-Saylan, M; Sabo, R; Wang, Y | 1 |
| Couturier, A; Dejager, S; Foley, JE; Schweizer, A | 1 |
| Dole, WP; He, YL; Howard, D; Leon, S; Ligueros-Saylan, M; Riviere, GJ; Rosenberg, M; Sabo, R; Sunkara, G | 1 |
| Bloomgarden, ZT; Inzucchi, SE | 1 |
| Klein, HH; Meier, JJ; Schmidt, WE | 1 |
| Marrs, JC; Saseen, JJ | 1 |
| Lauster, CD; McKaveney, TP; Muench, SV | 1 |
| Scheen, AJ | 5 |
| Del Prato, S | 1 |
| Campestrini, J; Deacon, CF; He, YL; Holst, JJ; Ligueros-Saylan, M; Nielsen, JC; Riviere, GJ; Schwartz, S; Serra, D; Wang, Y | 1 |
| Amori, RE; Lau, J; Pittas, AG | 1 |
| Jennings, HR; Langley, AK; Suffoletta, TJ | 1 |
| Campestrini, J; Dole, WP; He, YL; Howard, D; Rosenberg, M; Sabo, R; Sunkara, G; Wang, Y | 1 |
| Bizot, MN; Dole, WP; He, YL; Howard, D; Leon, S; Ligueros-Saylan, M; Riviere, GJ; Sabo, R; Sunkara, G | 1 |
| El-Ouaghlidi, A; Foley, J; Holmes, D; Holst, JJ; Nauck, MA; Rehring, E; Schweizer, A | 1 |
| Balez, S; Campestrini, J; He, YL; Howard, D; Laurent, A; Ligueros-Saylan, M; Sabo, R; Sadler, BM; Wang, Y | 1 |
| Baggio, LL; Drucker, DJ; Flock, G; Longuet, C | 1 |
| Panina, G | 1 |
| Banerji, MA; Couturier, A; Dejager, S; Pi-Sunyer, FX; Pratley, RE; Rosenstock, J; Schweizer, A | 1 |
| Deacon, CF; Foley, JE; Gerchman, F; Holst, JJ; Kahn, SE; Ligueros-Saylan, MA; Marcovina, SM; Montgomery, B; Tong, J; Udayasankar, J; Utzschneider, KM; Watson, CE | 1 |
| Dunning, BE; Foley, JE; Jauffret, S; Lalanne, G; Mari, A; Nilsson, PM; Scherbaum, WA; Schweizer, A | 1 |
| Ayalasomayajula, SP; Campestrini, J; Dole, K; He, YL; Humbert, H; Ligueros-Saylan, M; Sunkara, G; Wang, Y | 1 |
| Baron, MA; Deacon, CF; Foley, JE; Holst, JJ; Landin-Olsson, M; Rendell, M; Rochotte, E; Rosenstock, J | 1 |
| Campestrini, J; Dole, WP; He, YL; Howard, D; Ligueros-Saylan, M; Nielsen, JC; Riviere, GJ; Rosenberg, M; Sabo, R; Wang, Y | 1 |
| Campestrini, J; Dole, K; Dole, WP; He, YL; Howard, D; Ligueros-Saylan, M; Marion, A; Pommier, F; Sabo, R; Sunkara, G; Wang, Y; Zhao, C | 1 |
| Ahrén, B; Foley, JE; Pacini, G; Schweizer, A; Tura, A | 1 |
| Bolli, G; Cohen, SE; Dotta, F; Rochotte, E | 1 |
| Azuma, K; Cobelli, C; Dalla Man, C; Deacon, CF; Foley, JE; He, Y; Holst, JJ; Kangani, C; Kelley, DE; Ligueros-Saylan, M; Mancino, J; Rádiková, Z; Serra, D; Thomas, E; Toledo, FG | 1 |
| Banerji, MA; Dejager, S; Foley, JE; Mills, D; Pi-Sunyer, FX; Pratley, RE; Rosenstock, J; Schweizer, A | 1 |
| Garber, AJ; Sharma, MD | 1 |
| Cefalu, WT; Urquhart, S | 1 |
| Foley, JE; Jauffret, S; Lalanne, G; Mari, A; Nilsson, PM; Scherbaum, WA; Schweizer, A | 1 |
| Göke, B | 1 |
| Ahrén, B; Foley, JE | 1 |
| Fitchet, M; Rosenstock, J | 1 |
| Banerji, MA; Baron, MA; Camisasca, RP; Couturier, A; Ebeling, P; Foley, JE; Garber, AJ; Gudbjörnsdottir, S | 1 |
| Bock, G; Burton, DB; Camilleri, M; Deacon, CF; Foley, JE; Giesler, PD; Rizza, RA; Saylan, ML; Serra, DB; Vella, A | 1 |
| Barona, JP; Foley, JE; Mohideen, P; Niggli, M; Pan, C; Wang, Y; Yang, W | 1 |
| Dunning, BE; Foley, JE; Lalanne, G; Mari, A; Nilsson, PM; Scherbaum, WA; Schweizer, A; Wang, Y | 1 |
| Baron, M; Dejager, S; Fonseca, V; Shao, Q | 1 |
| Burkey, BF; Foley, JE; Hassiepen, U; Hoffmann, PK; Juedes, M; Trappe, J | 1 |
| Bandeira-Echtler, E; Bergerhoff, K; Lerch, CL; Richter, B | 1 |
| Campestrini, J; Flannery, B; He, YL; Jarugula, V; Leon, S; Ligueros-Saylan, M; Zinny, MA | 1 |
| Campestrini, J; He, YL; Jarugula, V; Leon, S; Ligueros-Saylan, M; Paladini, S; Sabia, H; Zhang, Y | 1 |
| Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S | 1 |
| Deacon, CF; Dunning, BE; Foley, JE; He, YL; Holst, JJ; Kelley, DE; Leone-Jones, A; Ligueros-Saylan, M; Yu, T | 1 |
| Pei, Z | 1 |
| Gadsby, R | 1 |
| Doupis, J; Veves, A | 1 |
| Calle Pascual, A; Dejager, S; Foley, J; Göke, B; Hershon, K; Kerr, D; Schweizer, A; Shao, Q | 1 |
| De Meester, I; Lambeir, AM; Scharpé, S | 1 |
| Balez, S; Bullock, J; Dole, WP; He, YL; Jarugula, V; Ligueros-Saylan, M; Riviere, GJ; Schwartz, S; Serra, D; Wang, Y | 1 |
| Davidson, JA; Gross, JL; Parente, EB | 1 |
| Dejager, S; Foley, J; Halimi, S; Minic, B; Schweizer, A | 1 |
| Deckert, F; Dole, WP; He, YL; Hu, P; Jiang, J; Kjems, L; Liu, D; Yin, Q | 1 |
| Cherrington, AD; Duttaroy, A; Edgerton, DS; Hobbs, CH; Johnson, KM; Neal, DW; Scott, M; Zhang, X | 1 |
| Faust, M; Matthes, J | 1 |
| Fonseca, VA; John-Kalarickal, J; Wani, JH | 1 |
| Bock, G; Camilleri, M; Cobelli, C; Dalla Man, C; Foley, JE; Giesler, PD; Ligueros Saylan, M; Rizza, RA; Serra, DB; Toffolo, G; Vella, A | 1 |
| Augustyns, K; Budde, P; De Meester, I; Jost, MM; Jürgens, M; Lambeir, AM; Lamerz, J; Menzel, C; Rose, H; Scharpé, S; Schulz-Knappe, P; Tammen, H; Zucht, HD | 1 |
| D'Alessio, DA; Denney, AM; Dunning, BE; Foley, JE; He, Y; Hermiller, LM; Martin, JM; Pratley, RE; Prigeon, RL; Saylan, ML; Tharp, WG | 1 |
| Croxtall, JD; Keam, SJ | 1 |
| Bosi, E; Lucotti, P; Monti, L; Piatti, PM; Setola, E | 1 |
| Seissler, J | 1 |
| Bandeira-Echtler, E; Bergerhoff, K; Lerch, C; Richter, B | 1 |
| Batard, Y; Einolf, H; Fischer, V; Gu, H; He, H; Howard, D; Mangold, JB; Smith, H; Tran, P; Wang, L; Yin, H | 1 |
| Filipeck, R; Fischer, V; Flood, D; He, H; Howard, D; Kramp, R; Smith, H; Tran, P; Yin, H | 1 |
| Gwaltney, SL | 1 |
| Boehnke, J; Boschmann, M; Budziarek, P; Dobberstein, K; Engeli, S; Foley, JE; He, Y; Jordan, J; Luft, FC; Strauss, A; Sweep, FC | 1 |
| Abe, N; Kato, M; Kikuchi, M; Mimori, N; Tachibana, H; Terao, S | 1 |
| Ahrén, B; Byiers, S; Dejager, S; Ferrannini, E; Fonseca, V; Matthews, D; Shao, Q; Zinman, B | 1 |
| Gupta, R; Pal, M; Parsa, KV; Singh, SK; Tokala, RK; Walunj, SS | 1 |
| Ahrén, B; Dejager, S; Dunning, BE; Foley, JE; Nilsson, PM; Persson, M; Schweizer, A | 1 |
| Siddiqui, NI | 1 |
| Goodman, M; Penman, J; Thurston, H | 1 |
| Hatakeyama, Y; Matsumoto, K; Mutoh, S; Takakura, S; Tanaka-Amino, K | 1 |
| Nicolucci, A; Rossi, MC | 1 |
| Barnett, AH; Piya, MK; Tahrani, AA | 1 |
| Bosi, E; Dotta, F; Goodman, M; Jia, Y | 1 |
| Degrande, E; Mathieu, C | 1 |
| Dole, WP; He, YL; Herron, J; Ligueros-Saylan, M; Picard, F; Sabo, R; Wang, Y | 1 |
| Maldonado-Lutomirsky, M; Niggli, M; Rosenstock, J | 1 |
| Scherbaum, WA | 1 |
| Mathieu, C | 1 |
| Barnett, AH | 1 |
| Paquot, N; Scheen, AJ | 1 |
| Gallwitz, B | 2 |
| Miuchi, M; Miyagawa, J; Nanba, M | 1 |
| Bosi, E; Dejager, S; Schweizer, A | 1 |
| Bolli, G; Colin, L; Dotta, F; Goodman, M; Minic, B | 1 |
| Buclin, T; Grouzmann, E; Livio, F | 1 |
| Brown, NJ; Byiers, S; Carr, D; Maldonado, M; Warner, BA | 1 |
| Banerji, MA; Baron, M; Blonde, L; Braceras, R; Dagogo-Jack, S; Marcellari, A; Pratley, RE; Purkayastha, D | 1 |
| Abid, K; Aubert, JF; Brakch, N; De Meester, I; Grouzmann, E; Lassahn, PG; Michalet, S; Rochat, B; Stöcklin, R; Tella, P; Vatansever, B | 1 |
| Bravis, V; Devendra, D; Gohel, B; Hassanein, M; Hui, E; Mehar, S; Salih, S | 1 |
| Foley, JE; Sreenan, S | 1 |
| Gallwitz, B; Thornberry, NA | 1 |
| Bell, PM; Duffy, NA; Flatt, PR; Green, BD; Lindsay, JR; McKillop, AM; O'Harte, FP; Patterson, S | 1 |
| Banerjee, M; Soran, H; Younis, N | 1 |
| Barnett, AH; Palalau, AI; Piya, MK; Tahrani, AA | 1 |
| Balzarini, J; Cabrera, S; Camarasa, MJ; De Meester, I; Diez-Torrubia, A; García-Aparicio, C; Velázquez, S | 1 |
| Bodvarsdottir, TB; Gotfredsen, CF; Heller, RS; Karlsen, AE; Knudsen, LB; Vedtofte, L | 1 |
| Schubert-Zsilavecz, M; Steinhilber, D; Zettl, H | 1 |
| Ahrén, B; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, VA; Matthews, DR; Zinman, B | 1 |
| Baek, HS; Jin, HY; Liu, WJ; Park, JH; Park, TS | 1 |
| Bilo, HJ; Goudswaard, AN; Houweling, ST; Kleefstra, N; Kooy, A; van Hateren, KJ; Verhoeven, S | 1 |
| Dejager, S; Halimi, S; Raccah, D; Schweizer, A | 1 |
| Chou, KC | 1 |
| Buikema, H; de Boer, RA; Oeseburg, H; Silljé, HH; van der Harst, P; van Gilst, WH | 1 |
| Guerci, B; Halter, C | 1 |
| Couturier, A; Dejager, S; Foley, JE; Kothny, W; Ligueros-Saylan, M; Schweizer, A | 1 |
| Couturier, A; Foley, JE; Kothny, W; Ligueros-Saylan, M; Schweizer, A | 1 |
| Filozof, C; Gautier, JF | 1 |
| Couturier, A; Goodman, M; Haneda, M; Inaba, Y; Kikuchi, M; Koya, D; Mimori, N; Onishi, Y; Tobe, K | 1 |
| Ciccarelli, L; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Mereu, R; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA | 1 |
| Kuritzky, L | 1 |
| Iwamoto, Y; Kashiwagi, A; Mimori, N; Suzuki, M; Tachibana, H; Terao, S; Yamada, N | 1 |
| Fakhoury, WK; Lereun, C; Wright, D | 1 |
| Kitahara, Y; Miura, K; Yamagishi, S | 1 |
| Dole, WP; Foley, J; He, YL; Ligueros-Saylan, M; Schwartz, SL; Valencia, J; Zhang, Y | 1 |
| Clar, C; Cummins, E; Marien, M; Philip, S; Richter, B; Royle, P; Waugh, N | 1 |
| Ahren, B; Couturier, A; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, V; Matthews, DR; Zinman, B | 1 |
| Banerji, MA; Francis, BH; Purkayastha, D | 1 |
| Gerich, J | 1 |
| Moreira, RO; Nascimento, TS; Zagury, L; Zagury, RL | 1 |
| Foley, JE; Jordan, J | 1 |
| Liu, H; Wang, W; Wang, X; Xu, W; Zhang, D | 1 |
| He, YL; Ito, H; Sekiguchi, K; Terao, S; Yamaguchi, M | 1 |
| Döller, D; Haidinger, M; Hecking, M; Hörl, WH; Pleiner, J; Säemann, MD; Stemer, G; Voigt, HC; Weichhart, T; Werzowa, J | 1 |
| Barna, I; Király, K; Kozsurek, M; Lambeir, AM; Luyten, W; Puskár, Z; Rónai, AZ; Szalai, J; Szentirmay, A | 1 |
| Keating, GM | 2 |
| Burkey, BF; Duttaroy, A; Hughes, TE; Merriam, K; Ren, X; Subramanian, K; Voelker, F; Zhang, X | 1 |
| Ito, H; Mimori, N; Sekiguchi, K; Wajima, T; Yamaguchi, M | 1 |
| Dejager, S; Foley, JE; Kothny, W; Schweizer, A; Shao, Q | 1 |
| Ahrén, B; Bosi, E; Foley, JE | 1 |
| Deacon, CF; Foley, JE; Holst, JJ; Köthe, LD; Nauck, MA; Schweizer, A; Vardarli, I | 1 |
| Boudes, P; Viereck, C | 1 |
| Matsui, T; Nishino, Y; Takeuchi, M; Yamagishi, S | 1 |
| Andrei, G; Balzarini, J; Camarasa, MJ; De Meester, I; Diez-Torrubia, A; Snoeck, R; Velázquez, S | 1 |
| Dejager, S; Foley, JE; Kothny, W; Schweizer, A | 1 |
| Bourdel-Marchasson, I; Dejager, S; Schweizer, A | 1 |
| Seino, Y | 1 |
| Ahrén, B; Dejager, S; Dunning, BE; Foley, JE; Schweizer, A; Villhauer, EB | 1 |
| Dicker, D | 1 |
| Bunck, MC; Diamant, M; Eekhoff, EM; Foley, JE; Heine, RJ; Möller-Goede, DL; Nijpels, G; Poelma, M; Schweizer, A | 1 |
| Andrews, C; Barnett, A; Geransar, P; Hanif, W; Hassanein, M; Kamal, A; Lister, N; Malik, W | 1 |
| Avogaro, A; de Kreutzenberg, SV; Fadini, GP; Gjini, R | 1 |
| Iwamoto, Y | 1 |
| Deacon, CF; Hjøllund, KR; Holst, JJ | 1 |
| Dole, WP; He, YL; Ligueros-Saylan, M; Serra, D; Wang, Y; Zhang, Y | 1 |
| Schneider, SH; Stamataros, G | 1 |
| Groop, PH; Kothny, W; Lukashevich, V; Schweizer, A; Shao, Q | 1 |
| Kalra, S | 1 |
| Albuquerque, JL; Alves, Gdos S; Canadas, V; Cunha, RA; Ferreira, VM; Gusmão, A; Ibiapina, GR; Lima, JG; Montenegro, L; Nóbrega, LH; Pontes, L; Pontes, S; Vilar, L | 1 |
| Netea, MG; Smits, P; Tack, CJ; van Poppel, PC | 1 |
| Fan, L; Gruenberger, JB; Kantor, E; Signorovitch, JE; Swallow, E; Wu, EQ | 1 |
| Chen, W; Chi, Y; Han, J; Huang, W; Ni, S; Qian, H; Yang, B; Zhang, H; Zhou, J; Zhou, Y | 1 |
| Gibbs, JP; Greene, RJ; Greg Slatter, J; Tu, H | 1 |
| Jermendy, G | 2 |
| Abe, M; Higuchi, T; Ito, M; Kikuchi, F; Maruyama, N; Okada, K; Sasaki, H; Soma, M; Tsuchida, M | 1 |
| de Boer, RA; Meissner, M; Silljé, HH; van Gilst, WH; Yin, M | 1 |
| Bianchi, R; Burkey, B; Cavaletti, G; Cervellini, I; Ghezzi, P; Lauria, G; Oggioni, N; Porretta-Serapiglia, C | 1 |
| Bunck, MC; Diamant, M; Eekhoff, EM; Foley, JE; Heine, RJ; Nijpels, G; Poelma, M; Schweizer, A | 1 |
| Akarte, AS; Gandhi, S; Srinivasan, BP | 1 |
| Barbee, T; Correa, I; Fredrickson, J; Gibbs, JP; Gibbs, MA; Lin, SL; Smith, B | 1 |
| Cai, L; Cai, Y; Liu, P; Lu, ZJ; Zhang, Y | 1 |
| Arni, S; Baerts, L; De Meester, I; Jungraithmayr, W; Matheeussen, V; Weder, W | 1 |
| Chattipakorn, N; Chattipakorn, S; Chinda, K; Palee, S; Phornphutkul, M; Surinkaew, S | 1 |
| Kadowaki, T; Kubota, N; Muraoka, T; Nakamura, A; Orime, K; Sato, K; Shinoda, K; Shirakawa, J; Terauchi, Y; Togashi, Y | 1 |
| Derosa, G; Maffioli, P | 1 |
| He, YL | 1 |
| Bader, G; Han, P; Liu, J; Lu, J; Lv, X; Ma, J; Pan, C; Xing, X; Zheng, S | 1 |
| Dotta, F; Fondelli, C; Guarino, E; Nigi, L; Patti, A | 1 |
| Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM | 1 |
| He, YL; Jusko, WJ; Landersdorfer, CB | 2 |
| He, YL; Irie, S; Ito, H; Sekiguchi, K; Shimada, S; Terao, S; Yamaguchi, M | 1 |
| Dorso, C; Hamann, L; Harstad, E; Kirby, MS; Kopcho, L; Langish, R; Locke, G; Marcinkeviciene, J; Shipkova, P; Wang, A | 1 |
| Barden, AT; Salamon, B; Schapoval, EE; Steppe, M | 1 |
| Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Maffioli, P; Ragonesi, PD; Romano, D | 1 |
| Maeda, S; Matsui, T; Yamagishi, S | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H | 3 |
| Dejager, S; Foley, JE; Schweizer, A | 1 |
| Fisman, EZ; Goldenberg, I; Klempfner, R; Leor, J; Tenenbaum, A | 1 |
| Barbieri, M; Marfella, R; Paolisso, G; Rizzo, MR | 1 |
| Groop, PH; Kothny, W; Lukashevich, V; Shao, Q | 1 |
| Baerts, L; D'Haese, PC; De Beuf, A; De Meester, I; Glorie, LL; Hermans, N; Magielse, J; Matheeussen, V; Verhulst, A | 1 |
| Ishikawa, M; Yamada, Y | 1 |
| Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D | 1 |
| Colette, C; Dejager, S; Guerci, B; Huet, D; Monnier, L; Petit, C; Quéré, S; Raccah, D; Serusclat, P; Valensi, P | 1 |
| Cavadas, C; Cortez, V; Estrada, M; Grouzmann, E; Marques, AP; Rosmaninho-Salgado, J; Santana, M | 1 |
| Inaba, W; Kamata, K; Mizukami, H; Takahashi, K; Tsuboi, K; Yagihashi, S | 2 |
| Asahara, S; Bartolome, A; Etoh, H; Fuchita, M; Hashimoto, N; Hosooka, T; Inoue, H; Kanno, A; Kido, Y; Koyanagi-Kimura, M; Matsuda, T; Mieda, Y; Seino, S; Shimizu, S; Takahashi, H; Teruyama, K | 1 |
| Ahrén, B; Farngren, J; Foley, JE; Persson, M; Schweizer, A | 2 |
| Ando, K; Irako, T; Nishimura, R; Sakamoto, M; Tsujino, D; Utsunomiya, K | 1 |
| Busch, SJ; Foley, JE; Hoffmann, P; Johnson, R; Kothny, W; Meyer, F; Sahota, P | 1 |
| Hamamoto, S; Hashiramoto, M; Kaku, K; Kanda, Y; Kohara, K; Shimoda, M; Tatsumi, F; Tawaramoto, K | 1 |
| Nakamura, A; Terauchi, Y | 1 |
| Abe, Y; Anabuki, J; Fukuda-Tsuru, S; Ishii, S; Yoshida, K | 1 |
| Aulinger, BA; D'Alessio, DA; Greer, TM; Hassel, JL; Jessen, L; Roy, KJ; Seeley, RJ; Smith, EP; Woods, SC | 1 |
| Foley, J; Gallwitz, B; Kothny, W; Kozlovski, P; Lukashevich, V; Shao, Q | 1 |
| Buikema, H; Deelman, LE; Hammes, HP; Henning, RH; Landheer, S; van Amerongen, A; van Gilst, WH; Wang, Y | 1 |
| de Beer, D; Fey, SJ; Joubert, E; Louw, J; Malherbe, CJ; Muller, CJ; Sanderson, M | 1 |
| Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Ragonesi, PD | 2 |
| Higashi, Y; Inoue, G; Nakata, H; Ohtomo, Y; Otsu, S; Sugitani, S; Yamaji, S | 1 |
| Barbieri, M; Campitiello, F; Canonico, R; Canonico, S; Carbonara, O; Della Corte, A; Ferraraccio, F; Gualdiero, P; Marfella, R; Padovano, V; Paolisso, G; Paolisso, P; Petrella, A; Petronella, P; Rizzo, MR; Sasso, FC | 1 |
| Matikainen, N; Taskinen, MR | 1 |
| Chattipakorn, N; Chattipakorn, SC; Pintana, H; Pipatpiboon, N; Pratchayasakul, W | 1 |
| Favarato, D; Garzillo, CL; Girardi, P; Hueb, W; Kalil Filho, R; Lima, EG; Rahmi, RM; Ramires, JA; Rezende, PC; Strunz, CM; Takiuti, M; Uchida, AH | 1 |
| Akishita, M; Hanaoka, Y; Honda, M; Iijima, K; Koshiyama, D; Ota, H; Ouchi, Y; Yagi, T; Yamaguchi, Y; Yamamoto, H; Yonenaga, A | 1 |
| Bhat, N; Krishnamurthy, AN; Kunjathaya, P; Ramaswami, PK | 1 |
| Itoh, H; Saisho, Y | 1 |
| Akhtar, M; Imran, M; Khan, S; Najmi, AK; Pillai, KK | 1 |
| Bakris, GL; Flynn, C | 1 |
| Barbieri, M; Boccardi, V; Esposito, A; Marfella, R; Pansini, A; Paolisso, G; Rizzo, MR | 1 |
| Dickinson, S; Foley, JE; Groop, PH; Kothny, W; Lukashevich, V; Schweizer, A | 1 |
| Döller, D; Frantal, S; Haidinger, M; Hecking, M; Lechner, F; Pacini, G; Pleiner, J; Säemann, MD; Stemer, G; Werzowa, J | 1 |
| Berndt-Zipfel, C; Dworak, M; Forst, T; Klamp, I; Löffler, A; Mitry, M; Pfützner, A | 1 |
| Dhakad, PK; Joshi, M; Joshi, S; Kanawat, DS; Kurmi, MK; Mishra, A; Raikwar, SK; Sharma, AK; Sharma, P; Srinivasan, BP; Srivastava, V | 1 |
| Aouidad, I; Crickx, B; Descamps, V; Deschamps, L; Fite, C; Marinho, E | 1 |
| Genovese, S; Tedeschi, D | 1 |
| Ahrén, B; Foley, JE; Kothny, W; Schweizer, A | 1 |
| Gombar, VK; Hall, SD | 1 |
| Blétry, O; Bouilloud, F; Crickx, E; Kahn, JE; Le Beller, C; Marroun, I; Schoindre, Y; Veyrie, C | 1 |
| Akahoshi, F; Ishii, S; Kadowaki, T; Kishida, H; Miyaguchi, I; Nabeno, M; Tanaka, Y | 1 |
| Asakura, M; Asano, Y; Asanuma, H; Ishibashi-Ueda, H; Ito, S; Kitakaze, M; Liao, Y; Min, KD; Minamino, T; Mochizuki, N; Sanada, S; Shindo, K; Takahashi, A; Takashima, S; Yamazaki, S; Yan, Y | 1 |
| Araújo, GR; Ávila, Dde L; Costa, DC; de Lima, WG; Diniz, MF; Miranda, PH; Pedrosa, ML; Silva, M; Silva, ME | 1 |
| Bader, G; Geransar, P; Schweizer, A | 1 |
| Berndt-Zipfel, C; Dworak, M; Forst, T; Löffler, A; Michelson, G; Mitry, M; Pfützner, A | 1 |
| García-Ortega, YE; Gómez-Gaitán, EA; González-Ortiz, LJ; González-Ortiz, M; Martínez-Abundis, E; Pérez-Rubio, KG; Robles-Cervantes, JA; Sánchez-Peña, MJ | 1 |
| Dengler, TJ; Doesch, AO; Ehlermann, P; Erbel, C; Frankenstein, L; Gleißner, C; Gueler, I; Helmschrott, M; Katus, HA; Mueller, S; Oeing, CU; Ruhparwar, A | 1 |
| Ahrén, B; Ekblad, E; Foley, JE; Omar, BA; Vikman, J; Voss, U; Winzell, MS | 1 |
| Andrews, C; Azam, M; Barnett, AH; Geransar, P; Hanif, W; Hassanein, M; Kamal, A; Malik, W | 1 |
| Assmann, G; Brenner, C; Brunner, S; David, R; Franz, WM; Gross, L; Mueller-Hoecker, J; Nathan, P; Steinbeck, G; Theiss, HD; Vallaster, M; Vogeser, M | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Deacon, CF; Hartmann, B; Holst, JJ; Hovendal, C; Knop, FK; Meisner, S; Plamboeck, A; Svendsen, LB; Veedfald, S; Vilsbøll, T; Wettergren, A | 1 |
| Morley, JE; Sinclair, A | 1 |
| Hoellinger, MJ; Kothny, W; Lukashevich, V; Paldánius, PM; Strain, WD | 1 |
| Kožnarová, R | 1 |
| Bae, JH; Cho, YM; Jung, HS; Kim, SY; Kim, YG; Oh, TJ; Park, KS | 1 |
| Forst, T; Foteinos, G; He, YL; Kulmatycki, K; Mattapalli, D; Neelakantham, S; Taylor, A | 1 |
| He, YL; Kulmatycki, K; Ligueros-Saylan, M; Reynolds, C; Taylor, A; Zhang, Y; Zhou, W | 1 |
| Furihata, K; He, YL; Kulmatycki, K; Mita, S; Saji, T; Sekiguchi, K; Yamaguchi, M | 1 |
| Aydogdu, A; Bozoglu, E; Doruk, H; Naharci, MI; Safer, U; Tasci, I; Yilmaz, BF; Yilmaz, G | 1 |
| Chatterjee, S | 1 |
| Akaishi, T; Aoki, M; Hasegawa, T; Kikuchi, A; Tateyama, M | 1 |
| Ji, LN; Li, H; Li, Q; Li, QF; Lu, JM; Pan, CY; Peng, YD; Tian, HM; Wang, L; Wang, XL; Yao, C; Zhang, RY; Zhao, ZG | 1 |
| Bader, G; Barnett, AH; Brath, H; Conget, I; de Castro, JJ; Göke, R; Kothny, W; Márquez Rodriguez, E; Mathieu, C; Nilsson, PM; Pagkalos, E; Penfornis, A; Schaper, NC; Wangnoo, SK | 1 |
| Hirano, T; Itoh, F; Katayama, Y; Kohashi, K; Nagashima, M; Nogi, Y; Nohtomi, K; Sato, K; Sinmura, K; Terasaki, M; Tomoyasu, M; Watanabe, T | 1 |
| Al-Arouj, M; Chawla, MS; Ditommaso, S; Hassoun, AA; Hristoskova, S; Kadwa, MY; Medlej, R; Pathan, MF; Shaltout, I | 1 |
| Kosaka, T; Kuwahara, Y; Nakamura, K; Otsuki, H; Shimomura, F; Tsukamoto, T | 1 |
| Buikema, H; Deelman, LE; Dokkum, RP; Henning, RH; Landheer, SW; Vavrinec, P; Wang, Y | 1 |
| Ahmed, I | 1 |
| Ishibashi, Y; Maeda, S; Matsui, T; Nakashima, S; Nishino, Y; Ojima, A; Yamagishi, S; Yamakawa, R; Yoshida, Y | 1 |
| Pradeepkumar, M; Rao, VJ; Satheeshkumar, N; Shanthikumar, S | 1 |
| Abe, H; Fujitani, Y; Hara, A; Ishibashi, K; Kanazawa, A; Kawamori, R; Komiya, K; Ogihara, T; Tamaki, M; Uchida, T; Watada, H | 1 |
| Basavan, D; Chinni, S; Dubala, A; Khatwal, RB; Kosaraju, J; Murthy, V; Muthureddy Nataraj, SK | 1 |
| Aleksandrov, AA; Chernova, TO; Dedov, II; Il'in, AV; Shestakova, MV; Shmushkovich, IA; Suhareva, OIu | 1 |
| Begum, SS; Hausenloy, DJ; Mocanu, MM; Riksen, N; Theodorou, L; Whittington, HJ; Wynne, AM; Yellon, DM | 1 |
| Dahal, UP; Gilbert, AM; Obach, RS | 1 |
| Balzarini, J; Cabrera, S; Camarasa, MJ; de Castro, S; De Meester, I; Diez-Torrubia, A; García-Aparicio, C; Mulder, G; Velázquez, S | 1 |
| Araki, E; Goto, R; Igata, M; Kawasaki, S; Kawashima, J; Kitano, S; Kondo, T; Matsumura, T; Matsuyama, R; Miyagawa, K; Motoshima, H; Ono, K | 1 |
| Araga, M; Del Prato, S; Kothny, W; Lukashevich, V | 1 |
| Tundis, R; Xiao, J | 1 |
| Antlanger, M; Döller, D; Haidinger, M; Hecking, M; Kopecky, C; Kovarik, JJ; Pacini, G; Pleiner, J; Säemann, MD; Stemer, G; Werzowa, J | 1 |
| Anz, D; Bourquin, C; Endres, S; Haubner, S; Kruger, S; Rapp, M | 1 |
| Bader, G; Dworak, M; Göke, R; Gruenberger, JB | 1 |
| Brada, M; Dohnalová, L; Edelsberger, T; Gerle, J; Haluzík, M; Houdová, J; Veselá, V | 1 |
| Chattipakorn, N; Chattipakorn, S; Chinda, K; Sanit, J | 1 |
| Goto, C; Mizui, T; Ohta, H; Tachi, T; Teramachi, H; Toyoshima, M; Tsuchiya, T | 1 |
| Aoki, K; Kamiko, K; Kamiyama, H; Masuda, K; Noguchi, Y; Tajima, K; Terauchi, Y | 1 |
| Araki, S | 1 |
| Baeschlin, DK; Beswick, M; Clark, DE; Duttaroy, A; Fenton, G; Ferreira, S; Flohr, S; Gerhartz, B; Gessier, F; Hassiepen, U; Namoto, K; Ostermann, N; Sedrani, R; Sirockin, F; Sutton, JM; Trappe, J | 1 |
| Bentley, P; Burkey, B; Busch, S; Chibout, SD; Dubost, V; Flavahan, N; Hayes, M; Hoffmann, P; Kaushik, V; Lapadula, D; Longo, L; Martin, L; Moulin, P; Pantano, S; Sahota, P; Schoenfeld, H; Spaet, R; Zhou, W | 1 |
| Breitschaft, A; Darstein, C; Golor, G; Hermosillo Reséndiz, K; Hu, K | 1 |
| Honka, M | 1 |
| Gresnigt, MS; Netea, MG; Smits, P; Tack, CJ; van Poppel, PC | 1 |
| Aravind, SR | 1 |
| Akagi, S; Akazawa, K; Ito, H; Miura, D; Miyoshi, T; Nakamura, K; Oe, H; Sugiyama, H; Wada, J; Yonezawa, T; Yoshida, M | 1 |
| Davis, SN; Lamos, EM; Stein, SA | 1 |
| Abdel-Aziz, O; Abdel-Ghany, MF; Ayad, MF; Tadros, MM | 1 |
| Abdul-Ghani, M; Cakirca, M; Camli, AA; Cikrikcioglu, MA; Erkoc, R; Hursitoglu, M; Kanat, M; Karatoprak, C; Kiskac, M; Soysal, P; Zorlu, M | 1 |
| Barden, AT; Piccoli, BL; Schapoval, EE; Steppe, M; Volpato, NM | 1 |
| Ahrén, B; Bader, G; Foley, JE; Mathieu, C; Schweizer, A | 1 |
| Calado, F; Carvalho, D; Gruenberger, JB; Johal, S; Ong, SH; Silva-Nunes, J; Viana, R; Viriato, D | 1 |
| Athyros, VG; Elisaf, MS; Filippatos, TD | 1 |
| Costa, TD; de Andrade, C; de Araújo Lock, G; de Araújo, BV; Haas, SE; Pigatto, MC | 1 |
| Burlina, S; Chilelli, NC; Lapolla, A; Sartore, G | 1 |
| Górska, J; Rokicka, D; Sędek, Ł; Strojek, K; Szczepański, T; Szymborska-Kajanek, A; Wróbel, M | 1 |
| Daci, E; Hoste, J; Mathieu, C | 1 |
| Kothny, W; Kozlovski, P; Li, Y; Lukashevich, V; Lv, X; Ma, J; Sun, F; Wang, W; Woloschak, M; Xing, X; Yang, W; Yuan, G | 1 |
| Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D | 2 |
| Bramlage, P; Forst, T | 1 |
| Ding, M; Li, CJ; Liu, XJ; Yu, DM; Yu, P; Yu, Q; Zhang, QM | 1 |
| Auffret, M; Babai, S; Béné, J; Coupe, P; Gautier, S; Hillaire-Buys, D; Jacobsoone, A; Jean-Pastor, MJ; Tronquoy, AF; Vermersch, A; Vonarx, M | 1 |
| Del Prato, S; Foley, JE; Kothny, W; Kozlovski, P; Matthews, DR; Paldánius, PM; Stumvoll, M | 1 |
| Almada, J; Angel, ID; Márquez-Rodríguez, E; Mendivil, CO; Paz, G; Rodríguez, C; Szyskowsky, O | 1 |
| Avogaro, A; Dardano, A; de Kreutzenberg, SV; Del Prato, S | 1 |
| Abdallah, K; Hassanein, M; Schweizer, A | 1 |
| Ahrén, B; Liehua, L; Marchetti, P; Omar, BA; Seino, Y; Yamada, Y | 1 |
| Navarro-Artieda, R; Sicras-Mainar, A | 1 |
| Horie, A; Ide, K; Ishizuka, T; Kanatsuka, A; Marumo, K; Oshikiri, K; Sunaga, M; Suzuki, Y; Tokuyama, Y | 1 |
| Choi, SA; Jang, JY; Jung, HS; Kim, HC; Kim, JH; Kim, MJ; Kim, SW; Lee, HM; Lee, KB; Ohn, JH; Park, KS; Yoon, JW | 1 |
| Asakura, M; Atsuda, K; Fujii, H; Fujiwara, R; Hayashida, K; Itoh, T; Nakajima, M; Nakano, M | 1 |
| de Francisco, TM; Gasparetto, JC; Gimenez, AC; Pontarolo, R; Pontes, FL; Ribeiro, RP | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, S; Chinda, K; Palee, S | 1 |
| Bando, YK; Ishii, M; Kambara, T; Kondo, K; Murohara, T; Nishimura, M; Ouchi, N; Shibata, R; Shimizu, Y; Tanigawa, T | 1 |
| Hirata, T; Ito, T; Kurita, N; Shimizu, S; Uchihara, H | 1 |
| Belle-van Meerkerk, G; Beulens, JW; Biesma, DH; de Ranitz-Greven, WL; de Valk, HW; Hoeks, LB | 1 |
| Dongre, N; Groop, PH; Kothny, W | 1 |
| Chen, LM; Guo, H; Guo, X; Kong, Y; Li, CJ; Li, DQ; Liu, DM; Wu, YJ; Yang, Y; Zhang, J | 1 |
| Okamoto, A; Sanada, H; Yokokawa, H | 1 |
| Cayasso, M; László, JF; Pórszász, R; Szalai, A; Újhelyi, J; Újhelyi, Z; Vecsernyés, M | 1 |
| Deacon, CF; Feinle-Bisset, C; Heruc, GA; Horowitz, M; Little, TJ; Luscombe-Marsh, N; Rayner, CK | 1 |
| Chattipakorn, N; Chattipakorn, SC; Pipatpiboon, N; Pratchayasakul, W; Sripetchwandee, J | 1 |
| Marchesini, G; Melchiorri, D; Montilla, S; Pani, L; Sammarco, A; Siviero, PD; Tomino, C; Trotta, MP | 1 |
| Deng, H; Li, Y; Lin, K; Wu, W; Xu, L; Zhang, W; Zhi, X | 1 |
| Casali, KR; Fofonka, A; Ribeiro, JP; Schaan, BD | 1 |
| Costa, DC; de Amorim Miranda, PH; de Lima, WG; Monteiro, OM; Rossoni, JV; Silva, ME | 1 |
| Bader, G; Blüher, M; Foley, JE; Schweizer, A | 1 |
| Clifton, P | 1 |
| Goundan, PN; Mantzoros, CS; Underwood, P | 1 |
| Dütting, ED; Eschenbach, P; Göke, R | 1 |
| Basiak, M; Drożdż, M; Okopień, B; Stęposz, A; Strózik, A | 1 |
| Bialek, C; Brath, H; Gingl, E; Prager, R; Ratzinger, M; Resl, M | 1 |
| Abou Jaoude, E; Al-Arouj, M; DiTommaso, S; Fawwad, A; Latif, ZA; Orabi, A; Rosales, R; Shah, P; Vaz, J | 1 |
| Fujisawa, Y; Kobori, H; Kohno, M; Masaki, T; Mori, H; Nakano, D; Nishiyama, A; Ohmori, K; Rafiq, K; Rahman, A; Sufiun, A | 1 |
| Asakura, M; Atsuda, K; Fujii, H; Fujiwara, R; Itoh, T | 1 |
| Abdel-Aziz, O; Ayad, MF; Tadros, MM | 1 |
| Hirayama, A; Nagao, K; Takahashi, A; Tani, S | 1 |
| Itoh, T; Kajikuri, J; Komori, K; Koyama, A; Otsuka, R | 1 |
| Ahrén, B; Malmgren, S | 1 |
| Al-Mrabeh, A; Foley, JE; Hollingsworth, KG; Macauley, M; Schweizer, A; Smith, FE; Taylor, R; Thelwall, PE | 1 |
| Aldhubiab, BE; Alhaider, IA; Asif, AH; Attimarad, M; Gangadhar, N; Harsha, SN; Nair, AB; Srinivasan, S; Venugopala, KN | 1 |
| Chan, TW; Chen, X; Li, W; Wang, Z; Wong, YL; Yeung, HS | 1 |
| Akin, F; Ar, IB; Ayvaz, G; Dokmetas, HS; Keskin, L; Tasan, E; Uren, E | 1 |
| Al-Saber, FA; Bader, G; Haddad, J; Ibrahim, M; Jallo, MK; Saab, C; Steitieh, H | 1 |
| Abdelsalam, RM; Safar, MM | 1 |
| Brady, EM; Dales, J; Davies, MJ; Gray, LJ; Hanif, W; Khunti, K | 1 |
| Kobayashi, M; Nakajima, K; Niwa, T; Shimodaira, M | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Inthachai, T; Kumfu, S; Lekawanvijit, S; Pongkan, W | 1 |
| Fawwad, A; Hasan, MI; Hussain, S; Khan, MA; Khan, MI; Kumar, K; Mahar, SA; Maheshwary, N; Siddiqi, A | 1 |
| Godoy J, G; Gutiérrez, V; Montecinos, M; Yenes, A | 1 |
| Dworak, M; Forst, T; Koch, C | 1 |
| Nishikido, T; Node, K; Ohira, H; Oyama, J | 1 |
| Kothny, W; Li, L; Lukashevich, V; Lv, X; Ma, J; Ning, G; Wang, W; Woloschak, M; Yang, M | 1 |
| Choi, SH; Hong, AR; Hwangbo, Y; Jang, HC; Kim, KM; Ku, EJ; Lee, J; Lim, S; Moon, JH | 1 |
| Chattipakorn, N; Chattipakorn, SC; Pintana, H; Pongkan, W; Pratchayasakul, W | 1 |
| Deacon, CF; Hansen, M; Hartmann, B; Hjøllund, KR; Holst, JJ; Plamboeck, A; Wewer Albrechtsen, NJ | 1 |
| Foley, JE; Kothny, W; Lukashevich, V; Rendell, MS; Schweizer, A | 1 |
| Asahara, S; Bartolome, A; Inoue, H; Kanno, A; Kawamoto, T; Kido, Y; Koyanagi-Kimura, M; Matsuda, T; Matsuura, Y; Mieda, Y; Ogawa, W; Seino, S; Shimizu, S; Suzuki, E; Takahashi, H; Takai, T; Yokoi, N | 1 |
| Cosenso-Martin, LN; Giollo-Junior, LT; Vilela-Martin, JF | 1 |
| Ateyya, H | 1 |
| Dejager, S; Deschaseaux, C; Detournay, B; Halimi, S; Robert, J | 1 |
| Baerts, L; De Meester, I; Gil-Bazo, I; Jang, JH; Jungraithmayr, W; Limani, P; Waumans, Y; Weder, W; Yamada, Y | 1 |
| Del Prato, S; Evans, M; Kothny, W; Lukashevich, V; McInnes, G; Schweizer, A; Shao, Q; Stumvoll, M | 1 |
| Ishikawa, S; Kouzu, H; Kuno, A; Miki, T; Miura, T; Murase, H; Nishizawa, K; Ogasawara, M; Tanno, M; Tobisawa, T; Yano, T | 1 |
| Fan, X; Fan, Y; Li, X; Ren, F; Ren, G; Shen, C; Shen, J; Song, Y; Yang, J; Zhang, N; Zhang, Y; Zheng, H | 1 |
| Akhtar, M; Khan, S; Najmi, AK; Panda, BP | 1 |
| Jain, S; Sharma, B | 1 |
| Sugita, M | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC | 1 |
| Bhamidipati, RK; Gilibili, RR; Mullangi, R; Srinivas, NR | 1 |
| D'Angelo, A; Derosa, G; Franzetti, I; Maffioli, P; Querci, F | 1 |
| El Batch, MM; El Batsh, MM; Shafik, NM; Younos, IH | 1 |
| El-Sherbeeny, NA; Nader, MA | 1 |
| Devineni, SR; Dubey, SK; Kadirappa, A; Kumar, N; Kumar, P; Singh, G | 1 |
| Athanasiadou, E; Bekiari, E; Boura, P; Karagiannis, T; Liakos, A; Mainou, M; Papatheodorou, K; Rika, M; Rizava, C; Tsapas, A | 1 |
| Baerts, L; De Meester, I; Inci, I; Jang, JH; Jungraithmayr, W; Vliegen, G; Weder, W; Yamada, Y; Yoshino, I | 1 |
| Alam, MM; Jang, JH; Kang, DG; Kim, YC; Koh, YS; Lee, DH; Lee, DS; Lee, ES; Lee, HS; Manzoor, Z; Oh, H | 1 |
| Borg, M; Bound, MJ; Deacon, CF; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Wu, T; Zhang, X | 1 |
| Camacho-Martinez, F; Martín-Gutierrez, FJ; Mendonça, FM; Ríos-Martín, JJ | 1 |
| Bhosekar, V; Foley, JE; Kawamori, R | 1 |
| Béni, S; Fejős, I; Hu, W; Kazsoki, A; Sohajda, T; Szente, L; Zhou, W | 1 |
| Chitnis, SD; He, YL; Kulmatycki, K; Mita, S; Salunke, A; Suzuki, H; Zhou, W | 1 |
| Jing, W; Shunyou, D; Xiaochun, H; Xiaoyan, C; Yingyu, F; Yuyu, T | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Inthachai, T; Lekawanvijit, S | 1 |
| Chitnis, SD; Han, Y; Kulmatycki, K; Mita, S; Sunkara, G; Yamaguchi, M; Zhao, R | 1 |
| Bugáňová, M; Haluzík, M; Holubová, M; Kaválková, P; Kuneš, J; Kuzma, M; Maletínská, L; Pelantová, H; Šedivá, B; Sýkora, D; Železná, B; Zemenová, J | 1 |
| Babazono, T; Hanai, K; Uchigata, Y; Yoshida, N | 1 |
| Broschag, M; Deacon, CF; Foley, J; He, YL; Holst, JJ; Kind, J; Kjems, L; Köthe, LD; Nauck, MA | 1 |
| Asakura, M; Atsuda, K; Fujii, H; Fujiwara, R; Itoh, T; Mitsugi, R; Nagai, K; Yamashita, Y | 1 |
| Abdel-Rahman, SZ; El-Mesallamy, HO; Hamdy, NM; Mostafa, AM | 1 |
| Baranov, O; Deacon, CF; Holst, JJ; Kahle, M; Nauck, MA | 1 |
| Charbonnel, B; Dejager, S; Fiquet, B; Gautier, JF; Monguillon, P; Valensi, P; Verier-Mine, O | 1 |
| Abiru, N; Ando, T; Horie, I; Kawakami, A; Shigeno, R | 1 |
| Atsumi, T; Cho, KY; Dan-Noura, M; Koyanagawa, N; Miyoshi, H; Nakamura, A; Ono, K; Takano, Y; Yamamoto, K | 1 |
| Chattipakorn, N; Chattipakorn, SC; Pongkan, W; Pratchayasakul, W; Sa-Nguanmoo, P; Sivasinprasasn, S | 1 |
| Brath, H; Gawai, A; Mathieu, C; Paldánius, PM; Phadke, U; Prasanna Kumar, KM | 1 |
| Bader, G; Brath, H; Kolaczynski, WM; Nilsson, PM; Paldánius, PM | 1 |
| Caffrey, JL; Chang, CH; Chang, YC; Chuang, LM; Lai, MS; Lin, JW; Wu, LC | 1 |
| Emoto, N; Kato, K; Okajima, F; Sugihara, H | 1 |
| Ji, LN; Li, H; Li, Q; Li, QF; Lu, JM; Pan, CY; Peng, YD; Tian, HM; Wang, BH; Wang, L; Yao, C; Zhao, ZG; Zhu, DL | 1 |
| Ersoy-Evans, S; Gököz, O; Gönül, M; Keseroglu, HO; Taş-Aygar, G | 1 |
| Bingham-Gardiner, P; Bolodeoku, J; Hassan, SW; Lee, S; Scowcroft, A; Spencer, W; Tebboth, A | 1 |
| Cha, BS; Han, E; Kang, ES; Kim, BS; Kim, CS; Lee, BW; Lee, YH; Nam, JY; Park, SH | 1 |
| Furukawa, T; Kamoi, K; Kaneko, K; Kaneko, M; Maruyama, R; Ohara, N; Sato, K; Tanaka, J | 1 |
| El Sarha, A; Refaat, R; Sakr, A; Salama, M | 1 |
| Coughtrie, AL; Layton, D; Qayum, N; Shakir, SA | 1 |
| Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Kredphoo, S; Pintana, H; Pongkan, W; Sivasinprasasn, S | 1 |
| Jütte, H; Meier, J; Montanya, E; Nauck, M; Schmidt, W; Tannapfel, A; Ueberberg, S; Uhl, W | 1 |
| Evans, M; Foley, JE; Schweizer, A | 1 |
| Cho, YM; Jang, HC; Jung, HS; Kim, SY; Kwak, S; Park, KS | 1 |
| Bound, MJ; Deacon, CF; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Trahair, LG; Wu, T; Zhang, X | 1 |
| Mudher Mikhael, E | 1 |
| Al-Arouj, M; Hassoun, AA; Ibrahim, M | 1 |
| Bentley, P; Busch, S; Gunson, D; Hayes, M; Hoffmann, P; Keselica, M; Lapadula, D; Martin, L; Skuba, E | 1 |
| Asakura, M; Atsuda, K; Fujii, H; Fujiwara, R; Itoh, T; Karaki, F | 1 |
| Arao, T; Hajime, M; Kuno, F; Kurozumi, A; Mine, S; Miyazaki, M; Mori, H; Narisawa, M; Okada, Y; Sonoda, S; Sugai, K; Tanaka, K; Tanaka, Y; Torimoto, K | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Khamseekaew, J; Pintana, H; Siri-Angkul, N; Tanajak, P | 1 |
| Liu, G; Liu, X; Men, P; Wang, Y; Zhai, S | 1 |
| Asakura, M; Atsuda, K; Fujii, H; Fujiwara, R; Fukami, T; Itoh, T; Nakajima, M | 1 |
| Kanazawa, I; Kiyohara, N; Koike, S; Notsu, M; Sasaki, M; Sugimoto, T; Tada, Y; Tanaka, KI; Tanaka, S; Yamane, Y; Yamauchi, M | 1 |
| Fonseca, M; Kothny, W; Kozlovski, P; Lukashevich, V; Mohan, V; Odawara, M; Paldánius, PM | 1 |
| Kimura, K; Takayanagi, R; Uchida, T; Yamada, Y | 2 |
| Eom, YS; Gwon, AR; Kim, BJ; Kim, JY; Kim, KW; Kim, YS; Kwak, KM; Lee, K; Lee, S; Park, IB; Yu, SH | 1 |
| Chen, YW; Fu, CP; Lee, CL; Lee, IT; Lin, SY; Sheu, WH; Song, YM; Wang, JS | 1 |
| Bound, MJ; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Sun, Z; Trahair, LG; Wu, H; Wu, T; Zhang, X | 1 |
| Atsumi, T; Cho, KY; Kameda, H; Kimachi, K; Kondo, T; Miyoshi, H; Nagai, S; Nakamura, A; Nomoto, H | 1 |
| Hu, Z; Tang, Z; Wang, Z; Zhai, W; Zhang, M | 1 |
| Abdallah, DM; Al-Shorbagy, MY; Aldakinah, AA; El-Abhar, HS | 1 |
| Chattipakorn, N; Chattipakorn, SC; Pongkan, W; Pratchayasakul, W; Sivasinprasasn, S; Tanajak, P | 1 |
| Rakha, S; Shelbaya, S | 1 |
| Chu, C; de Vries, F; Kothny, W; Lopez-Leon, S; Schlienger, R; Serban, C; Williams, R | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Jiang, C; Li, X; Liang, G; Sa-Nguanmoo, P; Tanajak, P; Wang, X | 1 |
| Acurcio, FA; De Oliveira, GL; Godman, B; Guerra Júnior, AA | 1 |
| Chodick, G; Davis, C; Melzer Cohen, C; Shalev, V | 1 |
| Antonenko, V; Curato, C; Dwi Putra, SE; Falke, LG; Hasan, AA; Hocher, B; Klein, T; Mohagheghi Samarin, A; Reichetzeder, C; Rippmann, J; Tsuprykov, O; von Websky, K | 1 |
| Hemmingsen, B; Metzendorf, MI; Richter, B; Sonne, DP | 1 |
| Burkey, B; Duttaroy, A; Hu, J; Kawamori, D; Kulkarni, RN; Liew, CW; Morioka, T; Shirakawa, J | 1 |
| Eskenazi, D; Fisman, EZ; Goldenberg, I; Goldkorn, R; Klempfner, R; Leor, J; Naftali-Shani, N; Tenenbaum, A; Younis, A | 1 |
| Hua, WC; Li, CM; Liu, Q; Wang, H; Wang, LG | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N | 1 |
| Atkin, SL; Banach, M; Katsiki, N; Mikhailidis, DP; Pirro, M; Sahebkar, A | 1 |
| Hur, KY; Jin, SM; Kim, G; Kim, JH; Lee, MK; Oh, S | 1 |
| Cheng, F; Guo, X; He, J; Yuan, G; Zhang, J | 1 |
| Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Kerdphoo, S; Pratchayasakul, W; Sa-Nguanmoo, P; Tanajak, P | 1 |
| Billiar, TR; Fan, Y; Kang, R; Kroemer, G; Liu, J; Lotze, MT; Song, X; Sun, X; Tang, D; Xie, Y; Yuan, H; Zeh, HJ; Zhang, L; Zhong, M; Zhu, S | 1 |
| Chmelik, M; Harreiter, J; Kautzky-Willer, A; Kosi-Trebotic, L; Thomas, A; Trattnig, S | 1 |
| Abeni, D; Collina, MC; Di Zenzo, G; Didona, B; Fania, L; Mazzanti, C; Pagnanelli, G; Provini, A; Salemme, A | 1 |
| Aoki, S; Atsumi, T; Furumoto, T; Inoue, A; Kitao, N; Kurihara, Y; Manda, N; Miya, A; Miyoshi, H; Nakamura, A; Nomoto, H; Ono, K; Tsuchida, K; Yamamoto, C | 1 |
| Berger, D; Bernthaler, T; Eisenwort, G; Entner, M; Hadzijusufovic, E; Herrmann, H; Hoermann, G; Rülicke, T; Sadovnik, I; Stefanzl, G; Valent, P; Willmann, M | 1 |
| Li, M; Ping, F; Wang, T; Wang, X; Xiao, X; Yu, M; Zhang, Q; Zheng, J | 2 |
| Gladson, S; Karasawa, S; Nishimura, R; Shimomura, I; Suzuki, T; Tada, Y; Tatsumi, K; West, J | 1 |
| Cho, H; Kim, JH; Lee, BW; Lee, WJ; Song, SO; Suh, S | 1 |
| Bundhun, PK; Huang, F; Janoo, G; Teeluck, AR | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, S; Ittichaicharoen, J; Sa-Nguanmoo, P; Tanajak, P | 1 |
| Attila, T; Mungan, Z; Ünal Kabaoğlu, Z; Vural, M | 1 |
| Azuma, K; Goto, H; Ikeda, F; Kanazawa, A; Komiya, K; Masuyama, A; Mita, T; Ogihara, T; Ohmura, C; Osonoi, T; Osonoi, Y; Saito, M; Sato, J; Shimizu, T; Someya, Y; Suzuki, L; Takayanagi, N; Takeno, K; Uzawa, H; Watada, H | 1 |
| Ansari, MT; Baig, MMFA; Khan, GJ; Khan, S; Naeem, MA | 1 |
| Cavadas, C; Cunha-Santos, J; Leal, H; Marques, AP; Pereira de Almeida, L; Rosmaninho-Salgado, J; Sousa-Ferreira, L | 1 |
| Huang, M; Jiang, LF; Ma, QH; Mao, JL; Xu, WX | 1 |
| Hsiao, YC; Hung, YJ; Lee, TI; Lu, YC; Sheu, WH; Tsai, CL; Wang, JS; Yang, WS | 1 |
| Karkute, SG; Koley, TK; Maurya, A; Singh, B; Srivastava, S; Tripathi, A; Yengkhom, BK | 1 |
| Abdelaziz, RR; Abdelhamid, AM; Salem, HAA | 1 |
| Faria-Neto, JR; Lacerda, CS; Marino, EC; Pechmann, LM; Polesel, MG; Vianna, AGD | 1 |
| España, A; García-Díez, I; Hashimoto, T; Herrero-Gonzalez, JE; Iranzo, P; Ishii, N; Ivars-Lleó, M; López-Aventín, D; Pujol, RM | 1 |
| Abdel Ghafar, MT; Atlam, R; Elsaadany, A; Eshra, KA; Rizk, FH; Shaaban, AE; Shalaby, MM; Soliman, NA | 1 |
| Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Jiang, C; Kerdphoo, S; Li, X; Liang, G; Pratchayasakul, W; Sa-Nguanmoo, P; Tanajak, P; Wang, X | 1 |
| Berlanda, G; Bock, PM; Casali, KR; da Rosa, FM; da Silveira, AD; Fofonka, A; Schaan, BD | 1 |
| Abd-Elsalam, RM; Abdel-Rahman, RF; El-Marasy, SA | 1 |
| Jacob, L; Kostev, K; Schokker, E | 1 |
| Kaundal, PK; Mokta, JK; Mokta, K; Sahai, AK | 1 |
| Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Sun, Z; Wang, X; Wu, T; Xie, C | 1 |
| Cheng, CY; Chiang, CP; Chien, WC; Chung, CH; Hung, CT; Liu, JS; Wang, WM | 1 |
| Dicembrini, I; Mannucci, E; Monami, M; Montereggi, C; Nreu, B | 1 |
| Alenabi, F; Baltzinger, P; Borot, S; Chantrel, F; Cridlig, J; Dorey, F; Ducloux, D; Fleury, D; Guerci, B; Hadjadj, S; Hannedouche, T; Kessler, L; Klein, A; Kunz, K; Meyer, L; Meyer, N; Munch, M; Smagala, A; Verier-Mine, O; Winiszewski, P | 1 |
| Chin, KL; Hawley, CM; Jun, M; Lo, C; Oshima, M; Toyama, T; Zoungas, S | 1 |
| Abdelrahim, MEA; Elberry, AA; Hussein, RRS; Mohamed Rabea, A; Mohsen, M | 1 |
| Chen, Y; Dong, B; Hu, J; Wang, J; Wang, Y; Wang, Z | 1 |
| Abdel-Aal, M; Abdel-Ghany, RH; Alsemeh, AE; Ghareib, SA; Sabry, D; Wahba, NS | 1 |
| Cai, ZJ; Chen, T; Li, N; Lin, WQ; Liu, MB; Zheng, B | 1 |
| Gezawa, ID; Salawu, OA; Uloko, AE; Uloko, AT | 1 |
| Poonchuay, N; Uitrakul, S; Wattana, K | 1 |
| Fan, L; Ge, Q; Hou, Y; Hu, X; Li, X; Liu, J; Qin, G; Xiao, X; Yang, H; You, Y | 1 |
| Chepulis, L; Keenan, R; Lawrenson, R; Mayo, C; Paul, R | 1 |
117 review(s) available for adamantane and vildagliptin
| Article | Year |
|---|---|
Incretins: what does the future hold?
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Exenatide; Glucagon-Like Peptide 1; Humans; Liraglutide; Nitriles; Peptides; Protease Inhibitors; Pyrrolidines; Venoms; Vildagliptin | 2005 |
Diabetes: assessing the pipeline.
Topics: Adamantane; Alkanesulfonates; Amyloid; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exenatide; Glycine; Humans; Hypoglycemic Agents; Indoles; Islet Amyloid Polypeptide; Maleimides; Nitriles; Oxazoles; Peptides; Phenylpropionates; Piperidines; PPAR alpha; PPAR gamma; Protein Kinase C; Pyrazoles; Pyrrolidines; Receptor, Cannabinoid, CB1; Receptors, Glucagon; Rimonabant; Venoms; Vildagliptin | 2006 |
Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enzyme Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Isoenzymes; Nitriles; Pyrrolidines; Vildagliptin | 2006 |
[Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glycine; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Oxazoles; Peroxisome Proliferator-Activated Receptors; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes.
Topics: Adamantane; Animals; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Humans; Hypoglycemic Agents; Islets of Langerhans; Nitriles; Protease Inhibitors; Pyrrolidines; Stimulation, Chemical; Vildagliptin | 2006 |
DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Models, Animal; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
How do different GLP-1 mimetics differ in their actions?
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrrolidines; Venoms; Vildagliptin | 2006 |
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2006 |
Vildagliptin.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin | 2006 |
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Isoenzymes; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
Exenatide: a novel approach for treatment of type 2 diabetes.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Exenatide; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Humans; Hypoglycemic Agents; Insulin; Nitriles; Peptides; Pyrrolidines; Treatment Outcome; Venoms; Vildagliptin | 2006 |
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2007 |
[Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Insulin Resistance; Intestinal Mucosa; Nitriles; Peptide Hormones; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose; Glycoproteins; Homeostasis; Humans; Hypoglycemic Agents; Islets of Langerhans; Models, Biological; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2007 |
The role of vildagliptin in the management of type 2 diabetes mellitus.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
[New concepts in the treatment of type 2 diabetes].
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Nitriles; Peptides; Piperidines; Pyrazines; Pyrazoles; Pyrrolidines; Rimonabant; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Vildagliptin: a novel oral therapy for type 2 diabetes mellitus.
Topics: Adamantane; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Humans; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Delivery Systems; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2007 |
The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Risk Factors; Vildagliptin | 2007 |
DPP-4 inhibitors.
Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin | 2007 |
Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database.
Topics: Adamantane; Aged; Biomarkers; Blood Glucose; C-Peptide; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Multicenter Studies as Topic; Nitriles; Pyrrolidines; Vildagliptin | 2008 |
Update: vildagliptin for the treatment of Type 2 diabetes.
Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2008 |
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Exenatide; Gastric Emptying; Glucagon-Like Peptide 1; Hypoglycemic Agents; Incretins; Islets of Langerhans; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Clinical management strategies for type 2 diabetes.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin-Secreting Cells; Metformin; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gastric Emptying; Glucagon-Like Peptide 1; Glucose; Humans; Insulin Resistance; Islets of Langerhans; Lipid Metabolism; Liver; Nitriles; Pyrrolidines; Vildagliptin | 2008 |
Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes.
Topics: Adamantane; Aged; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin | 2008 |
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Topics: Adamantane; Body Weight; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nausea; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Vomiting | 2008 |
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
Topics: Adamantane; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Nitriles; Protein Conformation; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Structure-Activity Relationship; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
New treatments for type 2 diabetes--the DPP4 inhibitors.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin | 2007 |
DPP4 inhibitors: a new approach in diabetes treatment.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
DPP4 inhibitors for diabetes--what next?
Topics: Adamantane; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Hypoxia; Neoplasms; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Postprandial Period; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Combinations; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Metformin; Nitriles; Pyrrolidines; Tablets; Treatment Outcome; Vildagliptin | 2008 |
[Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin | 2008 |
Incretin-based therapies in type 2 diabetes: a review of clinical results.
Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.
Topics: Adamantane; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrrolidines; Uracil; Vildagliptin | 2008 |
Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2009 |
Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
Drug evaluation: vildagliptin-metformin single-tablet combination.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Lipids; Metformin; Nitriles; Practice Guidelines as Topic; Pyrrolidines; Safety; Treatment Outcome; Vildagliptin | 2009 |
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Topics: Adamantane; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Edema; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
Vildagliptin: a new oral treatment for type 2 diabetes mellitus.
Topics: Adamantane; Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Nitriles; Pyrrolidines; Severity of Illness Index; Time Factors; Treatment Outcome; Vildagliptin | 2008 |
The scientific evidence: vildagliptin and the benefits of islet enhancement.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Evidence-Based Medicine; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Islets of Langerhans; Metformin; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
Translating science into clinical practice: focus on vildagliptin in combination with metformin.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Thiazolidinediones; Vildagliptin | 2009 |
[The value of incretin based therapies].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2009 |
[Incretin related agents for treatment of diabetes mellitus].
Topics: Adamantane; Diabetes Mellitus; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2009 |
[Pharmacological sheet. Vildagliptin, oral administration (GALVUS)].
Topics: Adamantane; Contraindications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Metformin; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sensitivity and Specificity; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin | 2009 |
Vildagliptin in clinical practice: a review of literature.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Islets of Langerhans; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
DPP-4 inhibitors in clinical practice.
Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2009 |
Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors.
Topics: Adamantane; Amino Acid Sequence; Chemistry, Pharmaceutical; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells; Molecular Sequence Data; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2010 |
[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2010 |
[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2010 |
Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.
Topics: Adamantane; Administration, Oral; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin | 2010 |
Graphic rule for drug metabolism systems.
Topics: Adamantane; Animals; Benzimidazoles; Enzymes; Humans; Indazoles; Models, Theoretical; Nitriles; Pharmaceutical Preparations; Protein Folding; Purines; Pyrrolidines; Roscovitine; Time Factors; Vildagliptin | 2010 |
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population.
Topics: Adamantane; Cerebrovascular Disorders; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Vildagliptin | 2010 |
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Patient Compliance; Peptides; Piperidines; Precision Medicine; Primary Health Care; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2010 |
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Half-Life; Humans; Hypoglycemic Agents; Male; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2010 |
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Weight Loss | 2010 |
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Topics: Adamantane; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Nitriles; Peptides; Pyrazines; Pyrrolidines; Quality of Life; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; State Medicine; Thiazolidinediones; Triazoles; United Kingdom; Venoms; Vildagliptin | 2010 |
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
DPP-4 inhibitors: what may be the clinical differentiators?
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Nitriles; Pyrrolidines; Vildagliptin; Weight Gain | 2010 |
Vildagliptin: a review of its use in type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin | 2010 |
Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.
Topics: Adamantane; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2011 |
Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies.
Topics: Adamantane; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Consumer Product Safety; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Nitriles; Odds Ratio; Pyrrolidines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vildagliptin | 2011 |
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin | 2011 |
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Nitriles; Pyrrolidines; Vildagliptin | 2011 |
DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.
Topics: Adamantane; Cardiovascular Diseases; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Nitriles; Pyrrolidines; Risk Factors; Vildagliptin | 2011 |
[Vildagliptin].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2011 |
Vildagliptin in the treatment of type 2 diabetes mellitus.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Nitriles; Pyrrolidines; Vildagliptin | 2011 |
Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Half-Life; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Nitriles; Pyrrolidines; Vildagliptin | 2011 |
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Metformin; Nitriles; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Tablets; Treatment Outcome; Triazoles; Vildagliptin | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
Topics: Adamantane; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Vildagliptin | 2012 |
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain | 2012 |
Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Purines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Vildagliptin | 2012 |
Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Nitriles; Patient Selection; Pyrrolidines; Risk Assessment; Risk Factors; Treatment Outcome; Vildagliptin | 2012 |
Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Topics: Adamantane; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Metformin; Nitriles; Pyrrolidines; Tablets; Treatment Outcome; Vildagliptin | 2012 |
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Aged; Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Glycated Hemoglobin; Humans; Middle Aged; Nitriles; Patient Selection; Prediabetic State; Pyrrolidines; Risk Assessment; Severity of Illness Index; Treatment Outcome; Vildagliptin | 2012 |
Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus--targeting thrombogenesis.
Topics: Adamantane; Animals; Anti-Inflammatory Agents; Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Fibrinolytic Agents; Humans; Hypoglycemic Agents; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Thrombosis; Vildagliptin | 2013 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.
Topics: Adamantane; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin; Weight Gain | 2013 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
[Use of vildagliptin from an internal disease specialists point of view].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin | 2013 |
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Topics: Adamantane; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular System; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Lipids; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
[Diabetic nephropathy].
Topics: Adamantane; Aged; Aged, 80 and over; Aging; Albuminuria; Antihypertensive Agents; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Humans; Hypertension; Hypoglycemia; Hypoglycemic Agents; Kidney; Nitriles; Pyrrolidines; Renal Dialysis; Sulfonylurea Compounds; Vildagliptin | 2013 |
Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2014 |
Vildagliptin: a review of its use in type 2 diabetes mellitus.
Topics: Adamantane; Administration, Oral; Aged; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Vildagliptin | 2014 |
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin | 2014 |
Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Insulin; Metformin; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2014 |
Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes.
Topics: Adamantane; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Glycated Hemoglobin; Humans; Hypoglycemia; Nitriles; Practice Guidelines as Topic; Pyrrolidines; Quality of Life; Vildagliptin | 2015 |
Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes.
Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Fasting; Female; Humans; Linear Models; Male; Middle Aged; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Vildagliptin; Weight Gain; Weight Loss | 2014 |
Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Hospitalization; Humans; Nitriles; Piperidines; Pyrrolidines; Sitagliptin Phosphate; Uracil; Vildagliptin | 2014 |
Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Holidays; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Liraglutide; Nitriles; Observational Studies as Topic; Pioglitazone; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Vildagliptin; Weight Loss | 2015 |
Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients.
Topics: Adamantane; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Retrospective Studies; Vildagliptin | 2015 |
Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Nitriles; Pancreatitis; Pyrrolidines; Treatment Outcome; Vildagliptin | 2016 |
Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin.
Topics: Adamantane; Aged; Aged, 80 and over; Dipeptidyl-Peptidase IV Inhibitors; Drug Eruptions; Female; Humans; Linagliptin; Male; Nitriles; Pemphigoid, Bullous; Pyrrolidines; Vildagliptin | 2016 |
Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide-1 Receptor; Glucosides; Holidays; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Liraglutide; Nitriles; Peptides; Pyrrolidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Venoms; Vildagliptin | 2016 |
Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
Topics: Adamantane; Adiponectin; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Male; Middle Aged; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Vildagliptin | 2016 |
Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications.
Topics: Adamantane; Brazil; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Models, Economic; Nitriles; Pyrrolidines; Vildagliptin | 2017 |
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Nitriles; Peptides; Pyrrolidines; Randomized Controlled Trials as Topic; Risk Factors; Venoms; Vildagliptin | 2017 |
A network meta-analysis for efficacy and safety of seven regimens in the treatment of type II diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Treatment Outcome; Vildagliptin | 2017 |
Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: A systematic review and meta-analysis of controlled trials.
Topics: Adamantane; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Tumor Necrosis Factor-alpha; Vildagliptin | 2017 |
Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adamantane; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Nitriles; Pioglitazone; Pyrrolidines; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Vildagliptin | 2017 |
Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incidence; Neoplasms; Piperidines; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Uracil; Vildagliptin | 2020 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Glycated Hemoglobin; Graft Survival; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Kidney Transplantation; Nitriles; Pioglitazone; Postoperative Complications; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Transplant Recipients; Vildagliptin | 2020 |
162 trial(s) available for adamantane and vildagliptin
| Article | Year |
|---|---|
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enzyme Inhibitors; Female; Glycoproteins; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged; Models, Biological; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2005 |
Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.
Topics: Adamantane; Area Under Curve; Blood Glucose; Body Mass Index; C-Peptide; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Metformin; Middle Aged; Nitriles; Placebos; Protease Inhibitors; Pyrrolidines; Vildagliptin | 2005 |
Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin | 2005 |
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
Topics: Adamantane; Apolipoprotein B-48; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Intestinal Mucosa; Intestines; Lipids; Lipoproteins; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Time Factors; Treatment Outcome; Triglycerides; Vildagliptin | 2006 |
Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Double-Blind Method; Female; Glycated Hemoglobin; Glycoproteins; Humans; Male; Middle Aged; Nitriles; Placebos; Protease Inhibitors; Pyrrolidines; Vildagliptin | 2006 |
Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes.
Topics: Adamantane; Adult; Analysis of Variance; Blood Glucose; C-Peptide; Chromatography, Liquid; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Radioimmunoassay; Tandem Mass Spectrometry; Time Factors; Vildagliptin | 2007 |
Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.
Topics: Adamantane; Administration, Oral; Adult; Asian People; Black People; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fasting; Female; Glycated Hemoglobin; Hispanic or Latino; Humans; Hypoglycemic Agents; Kinetics; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; White People | 2007 |
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Enzyme Inhibitors; Female; Glucose; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Islets of Langerhans; Kinetics; Male; Middle Aged; Nitriles; Obesity; Pyrrolidines; Vildagliptin | 2007 |
Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Topics: Adamantane; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Edema; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Racial Groups; Rosiglitazone; Thiazolidinediones; Vildagliptin | 2007 |
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Ligands; Lipids; Male; Middle Aged; Nitriles; Pioglitazone; Proinsulin; Protease Inhibitors; Pyrrolidines; Thiazolidinediones; Treatment Failure; Treatment Outcome; Vildagliptin | 2007 |
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
Topics: Adamantane; Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Nitriles; Pioglitazone; Protease Inhibitors; Pyrrolidines; Thiazolidinediones; Treatment Outcome; Vildagliptin | 2007 |
Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Fasting; Female; Glycated Hemoglobin; Hemoglobins; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Nitriles; Placebos; Pyrrolidines; Time Factors; Treatment Outcome; Vildagliptin | 2007 |
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.
Topics: Adamantane; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Placebos; Pyrrolidines; Vildagliptin | 2007 |
Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycoproteins; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin.
Topics: Adamantane; Adult; Analysis of Variance; Area Under Curve; Chronic Disease; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Liver Diseases; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes.
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; United Kingdom; Vildagliptin | 2007 |
Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
Topics: Adamantane; Administration, Oral; Adult; Anticoagulants; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Interactions; Female; Health; Humans; Hypoglycemic Agents; Male; Nitriles; Pyrrolidines; Vildagliptin; Warfarin | 2007 |
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
Topics: Adamantane; Administration, Oral; Adult; Aged; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Half-Life; Humans; Hypoglycemic Agents; Male; Middle Aged; Nausea; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin; Vomiting | 2007 |
Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
Topics: Adamantane; Administration, Oral; Adult; Area Under Curve; Confidence Intervals; Cross-Over Studies; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Food-Drug Interactions; Half-Life; Humans; Hypoglycemic Agents; Male; Models, Statistical; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers.
Topics: Adamantane; Adolescent; Adult; Anti-Arrhythmia Agents; Cross-Over Studies; Digoxin; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.
Topics: Adamantane; Adult; Algorithms; C-Peptide; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glyburide; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
Topics: Adamantane; Administration, Oral; Adolescent; Adult; Algorithms; Analysis of Variance; Area Under Curve; Biological Availability; Body Mass Index; Body Weight; Cross-Over Studies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Half-Life; Humans; Hypoglycemic Agents; Injections, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Nitriles; Pyrrolidines; Sex Factors; Vildagliptin | 2007 |
Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy.
Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Nitriles; Pyrrolidines; Safety; Vildagliptin | 2007 |
The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.
Topics: Adamantane; Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Nitriles; Placebos; Pyrrolidines; Single-Blind Method; Vildagliptin | 2008 |
Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia.
Topics: Adamantane; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Models, Biological; Nitriles; Pyrrolidines; Vildagliptin | 2008 |
Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects.
Topics: Adamantane; Adult; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Male; Middle Aged; Nitriles; Pyrrolidines; Simvastatin; Vildagliptin | 2007 |
Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Topics: Adamantane; Blood Glucose; C-Peptide; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Humans; Inulin; Kinetics; Male; Nitriles; Placebos; Postprandial Period; Pyrrolidines; Vildagliptin | 2008 |
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
Topics: Adamantane; Administration, Oral; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Half-Life; Headache; Humans; Male; Middle Aged; Nausea; Nitriles; Pyrrolidines; Ramipril; Tablets; Tetrazoles; Valine; Valsartan; Vildagliptin | 2008 |
Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Topics: Adamantane; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Proinsulin; Pyrrolidines; Treatment Outcome; Vildagliptin | 2007 |
Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Treatment Outcome; Vildagliptin | 2008 |
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
Topics: Adamantane; Blood Glucose; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Islets of Langerhans; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin | 2008 |
Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Treatment Outcome; Vildagliptin | 2008 |
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2008 |
The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.
Topics: Adamantane; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drinking; Eating; Enteroendocrine Cells; Fasting; Gastric Emptying; Ghrelin; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Middle Aged; Nitriles; Organ Size; Placebos; Postprandial Period; Pyrrolidines; Satiation; Stomach; Vildagliptin | 2008 |
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
Topics: Acarbose; Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2008 |
Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia.
Topics: Adamantane; Adult; Analysis of Variance; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Insulin; Lipids; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Time Factors; Vildagliptin | 2008 |
Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus.
Topics: Adamantane; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Longitudinal Studies; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2008 |
Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers.
Topics: Adamantane; Adolescent; Adult; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Female; Food-Drug Interactions; Humans; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2008 |
Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects.
Topics: Adamantane; Adolescent; Adult; Area Under Curve; Chromatography, Liquid; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Tablets; Tandem Mass Spectrometry; Therapeutic Equivalency; Vildagliptin | 2008 |
Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.
Topics: Adamantane; Adult; Diabetes Mellitus, Type 1; Feeding Behavior; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Nitriles; Pyrrolidines; Vildagliptin | 2008 |
Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin.
Topics: Adamantane; Adult; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2008 |
Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
Topics: Adamantane; Adult; Aged; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Vildagliptin | 2008 |
Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers.
Topics: Adamantane; Administration, Oral; Adolescent; Adult; Asian People; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Nitriles; Pyrrolidines; Vildagliptin; Young Adult | 2009 |
Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes.
Topics: Adamantane; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Digestion; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Nitriles; Placebos; Postprandial Period; Pyrrolidines; Satiety Response; Vildagliptin | 2009 |
Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Islets of Langerhans; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.
Topics: Adamantane; Adipose Tissue; Adult; Aged; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Lipid Mobilization; Male; Middle Aged; Muscle, Skeletal; Nitriles; Norepinephrine; Oxidation-Reduction; Postprandial Period; Pyrrolidines; Vildagliptin | 2009 |
Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus.
Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Nitriles; Placebos; Pyrrolidines; Treatment Outcome; Vildagliptin; Young Adult | 2009 |
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Time Factors; Vildagliptin | 2009 |
Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.
Topics: Adamantane; Aged; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Topics: Adamantane; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Young Adult | 2009 |
Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
Topics: Adamantane; Adult; Aged; Americas; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin; Young Adult | 2009 |
Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes.
Topics: Adamantane; Adult; Aged; Algorithms; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Topics: Adamantane; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Metformin; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Edema; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Treatment Outcome; Vildagliptin; Weight Gain; Young Adult | 2009 |
Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Thiazolidinediones; Vildagliptin; Weight Gain; Young Adult | 2009 |
Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes.
Topics: Adamantane; Demography; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Time Factors; Treatment Outcome; Vildagliptin | 2009 |
Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
Topics: Adamantane; Cyclohexanes; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Nitriles; Phenylalanine; Pyrrolidines; Vildagliptin | 2009 |
Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Topics: Adamantane; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemic Agents; Metformin; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2010 |
A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Young Adult | 2010 |
Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus.
Topics: Adamantane; Aged; Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2010 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Vildagliptin | 2010 |
Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study.
Topics: Adamantane; Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Treatment Outcome; Vildagliptin | 2010 |
Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Time Factors; Treatment Outcome; Vildagliptin; Young Adult | 2010 |
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
Topics: Adamantane; Adolescent; Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin; Weight Gain; Young Adult | 2010 |
Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.
Topics: Adamantane; Adult; Aged; Area Under Curve; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2010 |
A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation.
Topics: Adamantane; Austria; Biomarkers; Blood Glucose; Clinical Protocols; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney Transplantation; Nitriles; Placebo Effect; Prospective Studies; Pyrrolidines; Research Design; Time Factors; Treatment Outcome; Vildagliptin | 2010 |
Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
Topics: Adamantane; Administration, Oral; Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucose; Humans; Incretins; Injections, Intravenous; Insulin; Insulin Secretion; Male; Middle Aged; Nitriles; Pyrrolidines; Up-Regulation; Vildagliptin | 2011 |
Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2011 |
The metabolic syndrome influences the response to incretin-based therapies.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Male; Metabolic Syndrome; Middle Aged; Nitriles; Peptides; Prognosis; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2011 |
Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
Topics: Adamantane; Adolescent; Adult; Cardiovascular Physiological Phenomena; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Health; Healthy Volunteers; Heart Conduction System; Heart Rate; Humans; Male; Middle Aged; Nitriles; Placebos; Pyrrolidines; Vildagliptin; Young Adult | 2011 |
Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Kidney Failure, Chronic; Male; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin; Young Adult | 2011 |
Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes.
Topics: Adamantane; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vasodilation; Vildagliptin | 2011 |
The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Renal Dialysis; Statistics, Nonparametric; Vildagliptin | 2011 |
Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients.
Topics: Adamantane; Aged; Alkaline Phosphatase; Biomarkers; Blood Glucose; Bone and Bones; Bone Resorption; Calcium; Collagen Type I; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Homeostasis; Humans; Insulin; Male; Middle Aged; Netherlands; Nitriles; Peptides; Phosphates; Postprandial Period; Pyrrolidines; Time Factors; Treatment Outcome; Vildagliptin | 2012 |
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
Topics: Adamantane; Adolescent; Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Young Adult | 2012 |
Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes.
Topics: Adamantane; Administration, Oral; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Glucagon-Like Peptide 1; Humans; Insulin; Male; Middle Aged; Models, Biological; Nitriles; Pyrrolidines; Vildagliptin | 2012 |
Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.
Topics: Adamantane; Administration, Oral; Adult; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Half-Life; Humans; Male; Middle Aged; Models, Biological; Nitriles; Pyrrolidines; Vildagliptin | 2012 |
Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes.
Topics: Adamantane; Adult; Analysis of Variance; Area Under Curve; Asian People; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Monitoring; Eating; Feeding Behavior; Female; Food-Drug Interactions; Glucagon-Like Peptide 1; Humans; Intestinal Absorption; Japan; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Treatment Outcome; Vildagliptin | 2012 |
Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
Topics: Adamantane; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Weight Loss | 2012 |
Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease.
Topics: Adamantane; Adiponectin; Atherosclerosis; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Humans; Hypoglycemic Agents; Inflammation; Inflammation Mediators; Interleukin-1beta; Interleukin-6; Israel; Matrix Metalloproteinase 9; Metformin; Nitriles; Platelet Function Tests; Prospective Studies; Pyrrolidines; Research Design; Thrombosis; Time Factors; Treatment Outcome; Vildagliptin | 2012 |
Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Inflammation; Interleukin-18; Interleukin-6; Male; Metformin; Middle Aged; Nitriles; Oxidative Stress; Postprandial Period; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2012 |
One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment.
Topics: Adamantane; Aged; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Male; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2012 |
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?
Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrazines; Pyrrolidines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin | 2012 |
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; France; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pilot Projects; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin; Young Adult | 2012 |
Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
Topics: Adamantane; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucagon-Secreting Cells; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Nitriles; Pyrrolidines; Vildagliptin; Young Adult | 2012 |
Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; C-Peptide; Cross-Over Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Japan; Male; Middle Aged; Monitoring, Ambulatory; Natriuretic Peptide, Brain; Nitriles; Pilot Projects; Plasminogen Activator Inhibitor 1; Postprandial Period; Predictive Value of Tests; Pyrazines; Pyrrolidines; Serum Albumin; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin | 2012 |
Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Asia; Australia; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; United States; Vildagliptin | 2013 |
Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study.
Topics: Adamantane; Adult; Chemokines; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Down-Regulation; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Intention to Treat Analysis; Intercellular Signaling Peptides and Proteins; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Resistin; Retinol-Binding Proteins, Plasma; Vildagliptin | 2012 |
Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes.
Topics: Adamantane; Aged; Aged, 80 and over; Capillaries; Chronic Disease; Diabetes Mellitus, Type 2; Diabetic Foot; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Gene Expression Regulation; Glucagon-Like Peptide 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Italy; Male; Middle Aged; Neovascularization, Physiologic; Nitriles; Oxidative Stress; Proteasome Endopeptidase Complex; Pyrrolidines; RNA, Messenger; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Vildagliptin; Wound Healing | 2012 |
The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes.
Topics: Adamantane; Biomarkers; Chylomicron Remnants; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hyperglycemia; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Meals; Nitriles; Particle Size; Postprandial Period; Pyrrolidines; Triglycerides; Vildagliptin | 2013 |
Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.
Topics: Adamantane; Atherosclerosis; Blood Glucose; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cytokines; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Inflammation; Nitriles; Oxidative Stress; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Tyrosine; Vildagliptin | 2013 |
Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Body Weight; Chi-Square Distribution; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Kidney; Male; Middle Aged; Nitriles; Pyrrolidines; Severity of Illness Index; Time Factors; Treatment Outcome; Vildagliptin | 2013 |
Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney Transplantation; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Pioglitazone; Pyrrolidines; Risk Factors; Thiazolidinediones; Treatment Outcome; Vildagliptin | 2013 |
Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus.
Topics: Adamantane; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Nitriles; Postprandial Period; Proinsulin; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2013 |
Vildagliptin more effectively achieves a composite endpoint of HbA₁c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment.
Topics: Adamantane; Aged; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin; Weight Gain | 2013 |
Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study.
Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Erythrocyte Deformability; Female; Germany; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Laser-Doppler Flowmetry; Male; Metformin; Microcirculation; Middle Aged; Nitriles; Pyrrolidines; Regional Blood Flow; Retinal Vessels; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Vildagliptin | 2013 |
Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels.
Topics: Adamantane; Adult; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Insulin; Insulin Secretion; Insulin-Secreting Cells; Kinetics; Male; Middle Aged; Nitriles; Obesity; Overweight; Pyrrolidines; Vildagliptin | 2013 |
RETRACTED: Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients.
Topics: Adamantane; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; GPI-Linked Proteins; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Lectins; Male; Metformin; Middle Aged; Nicotinamide Phosphoribosyltransferase; Nitriles; Pyrrolidines; Serpins; Vildagliptin | 2013 |
Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty.
Topics: Acetaminophen; Adamantane; Aged; Area Under Curve; Case-Control Studies; Dipeptidyl-Peptidase IV Inhibitors; Duodenal Ulcer; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Insulin-Secreting Cells; Male; Nitriles; Pylorus; Pyrrolidines; Vagotomy, Truncal; Vildagliptin | 2013 |
Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.
Topics: Adamantane; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Feasibility Studies; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Nitriles; Precision Medicine; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2013 |
Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring.
Topics: Adamantane; Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin; Young Adult | 2013 |
Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
Topics: Adamantane; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2013 |
Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study.
Topics: Adamantane; Age Factors; Asian People; Biomarkers; Body Mass Index; China; Clinical Protocols; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Research Design; Time Factors; Treatment Outcome; Vildagliptin | 2013 |
Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Inositol; Kidney Failure, Chronic; Male; Middle Aged; Nitriles; Prospective Studies; Pyrazoles; Pyrrolidines; Renal Dialysis; Serum Albumin; Thiazolidines; Vildagliptin | 2014 |
[A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition].
Topics: Absorptiometry, Photon; Adamantane; Blood Glucose; Body Composition; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin; Waist Circumference | 2013 |
Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2014 |
Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Kidney Transplantation; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2014 |
[Efficacy and safety of vildagliptin as a second-line therapy vs other oral antidiabetic agents in patients with type 2 diabetes: Czech results within the worldwide prospective cohort EDGE study].
Topics: Adamantane; Adult; Aged; Cohort Studies; Czech Republic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Vildagliptin; Weight Gain | 2013 |
Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.
Topics: Adamantane; Adolescent; Adult; Blood Glucose; Cyclohexanes; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Healthy Volunteers; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Liraglutide; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Nateglinide; Nitriles; Phenylalanine; Prognosis; Pyrrolidines; Somatostatin; Vildagliptin; Young Adult | 2014 |
The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus.
Topics: Acarbose; Adamantane; Adult; Aged; Cells, Cultured; Cross-Over Studies; Cytokines; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hypoglycemic Agents; Leukocytes, Mononuclear; Lymphocytes; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2014 |
Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
Topics: Adamantane; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Meals; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Treatment Outcome; Vildagliptin | 2014 |
Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients.
Topics: Adamantane; Adult; Aged; Arginine; C-Reactive Protein; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Female; Fibrinogen; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitric Oxide; Nitriles; Pyrrolidines; Vildagliptin | 2014 |
Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies.
Topics: Adamantane; Adult; Aged; Blood Glucose; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2014 |
Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Case-Control Studies; China; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Follow-Up Studies; Glycated Hemoglobin; Glycemic Index; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Prognosis; Pyrrolidines; Risk Factors; Sulfonylurea Compounds; Vildagliptin; Weight Gain; Young Adult | 2015 |
Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
Topics: Adamantane; Adiponectin; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dietary Fats; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Male; Metformin; Middle Aged; Nitriles; Proinsulin; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha; Vildagliptin | 2014 |
Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
Topics: Adamantane; Adult; Asian People; Blood Glucose; Body Weight; China; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2014 |
Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial.
Topics: Adamantane; Adolescent; Adult; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Intention to Treat Analysis; Metformin; Middle Aged; Nitriles; Obesity; Overweight; Pyrrolidines; Research Design; Vildagliptin; Young Adult | 2014 |
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Intention to Treat Analysis; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin; Weight Gain; Weight Loss | 2014 |
A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
Topics: Adamantane; Asia; Biomarkers; Blood Glucose; Body Weight; Counseling; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Europe; Fasting; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Medication Adherence; Middle Aged; Middle East; Nitriles; Office Visits; Pyrrolidines; Religion and Medicine; Telephone; Time Factors; Treatment Outcome; Vildagliptin | 2014 |
Improved Insulin Secretion by Autologous Islet Transplantation, Compared to Oral Antidiabetic Agents, After Distal Pancreatectomy.
Topics: Adamantane; Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; HMGB1 Protein; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans Transplantation; Male; Metformin; Middle Aged; Nitriles; Pancreatectomy; Pancreatic Neoplasms; Pyrrolidines; Transplantation, Autologous; Vascular Endothelial Growth Factor A; Vildagliptin | 2015 |
Patients with type 2 diabetes mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin.
Topics: Adamantane; Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Insulin; Male; Middle Aged; Nitriles; Placebos; Pyrrolidines; Vildagliptin | 2014 |
Dipeptidyl peptidase-4 inhibitor (vildagliptin) improves glycemic control after meal tolerance test by suppressing glucagon release.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Food; Glucagon; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2014 |
Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
Topics: Adamantane; Adolescent; Adult; Appetite Regulation; Cross-Over Studies; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Energy Intake; Energy Metabolism; Food-Drug Interactions; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Insulin; Insulin Secretion; Male; Middle Aged; Nitriles; Peptide Fragments; Peptide YY; Postprandial Period; Pyrrolidines; Vildagliptin; Young Adult | 2014 |
[Therapeutic effect of vildagliptin and insulin aspart injection in elderly patients with type 2 diabetes].
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections; Insulin Aspart; Nitriles; Pyrrolidines; Vildagliptin | 2014 |
Effects of vildagliptin compared with glibenclamide on glucose variability after a submaximal exercise test in patients with type 2 diabetes: study protocol for a randomized controlled trial, DIABEX VILDA.
Topics: Adamantane; Biomarkers; Blood Glucose; Brazil; Clinical Protocols; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Exercise Test; Glyburide; Glycated Hemoglobin; Hemodynamics; Humans; Hypoglycemic Agents; Nitriles; Oxidative Stress; Predictive Value of Tests; Prospective Studies; Pyrrolidines; Research Design; Time Factors; Treatment Outcome; Vildagliptin | 2014 |
Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Vildagliptin; Young Adult | 2015 |
Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus.
Topics: Adamantane; Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, LDL; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2015 |
Efficacy and tolerability of vildagliptin-based versus comparative dual therapy in type 2 diabetes : Results of the Austrian subpopulation of the EDGE study.
Topics: Adamantane; Administration, Oral; Austria; Biomarkers; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Prevalence; Pyrrolidines; Treatment Outcome; Vildagliptin | 2015 |
Effect of dipeptidyl peptidase-4 inhibitor, vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus.
Topics: Adamantane; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Male; Middle Aged; Nitriles; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrrolidines; Time Factors; Treatment Outcome; Vildagliptin | 2015 |
Effect of vildagliptin on hepatic steatosis.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Fatty Liver; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Triglycerides; Vildagliptin | 2015 |
Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study.
Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin, Isophane; Male; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin; Weight Gain | 2015 |
The effects and safety of vildagliptin on cardiac function after acute myocardial infarction.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Echocardiography, Doppler; Electrocardiography; Female; Follow-Up Studies; Glomerular Filtration Rate; Glycated Hemoglobin; Heart Function Tests; Humans; Incretins; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Nitriles; Pyrrolidines; Reference Values; Risk Assessment; Stroke Volume; Treatment Outcome; Vildagliptin | 2015 |
Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2015 |
Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial.
Topics: Adamantane; Aged; Blood Glucose; Brazil; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; United States; Vildagliptin | 2015 |
Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
Topics: Acarbose; Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Monitoring, Ambulatory; Nitriles; Pyrrolidines; Vildagliptin | 2015 |
A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin; Whey Proteins | 2016 |
Bioequivalence and food effect assessment for vildagliptin/metformin fixed-dose combination tablets relative to free combination of vildagliptin and metformin in Japanese healthy subjects.
Topics: Adamantane; Adult; Area Under Curve; Cross-Over Studies; Drug Combinations; Food-Drug Interactions; Humans; Hypoglycemic Agents; Male; Metformin; Nitriles; Pyrrolidines; Tablets; Therapeutic Equivalency; Vildagliptin | 2016 |
Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Topics: Adamantane; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2016 |
Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist.
Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Healthy Volunteers; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Peptide Fragments; Pyrrolidines; Vildagliptin | 2016 |
Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Topics: Adamantane; Aged; Combined Modality Therapy; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, Diabetic; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Down-Regulation; Drug Administration Schedule; Drug Therapy, Combination; Exercise Therapy; Feedback, Physiological; Female; Glucagon-Like Peptide 1; Humans; Male; Meals; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Vildagliptin | 2016 |
Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nitriles; Pilot Projects; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2016 |
Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus.
Topics: Adamantane; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Drug Substitution; Drug Therapy, Combination; Female; Humans; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Vildagliptin | 2016 |
Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin.
Topics: Adamantane; Adult; Aged; Apolipoprotein B-48; Biomarkers; Blood Glucose; Cholesterol; Chylomicrons; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fasting; Female; Follow-Up Studies; Glycemic Index; Humans; Hypoglycemic Agents; Insulin; Lipoproteins; Male; Middle Aged; Nitriles; Postprandial Period; Prognosis; Pyrrolidines; Triglycerides; Vildagliptin; Young Adult | 2017 |
Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
Topics: Adamantane; Aged; Asian People; Blood Glucose; Body Mass Index; China; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin | 2016 |
Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride.
Topics: Adamantane; Cardiovascular Diseases; Chemokine CXCL12; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Risk Factors; Sulfonylurea Compounds; Vildagliptin | 2017 |
Small Intestinal Glucose Delivery Affects the Lowering of Blood Glucose by Acute Vildagliptin in Type 2 Diabetes.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Duodenum; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Pyrrolidines; Vildagliptin | 2016 |
Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Glycated Hemoglobin; Humans; Male; Middle Aged; Nitriles; Piperidines; Pyrrolidines; Treatment Outcome; Uracil; Vildagliptin | 2017 |
Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2017 |
Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose.
Topics: Adamantane; Adult; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Circadian Rhythm; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Substitution; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Time Factors; Vildagliptin | 2017 |
The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study.
Topics: Adamantane; Aged; Biomarkers; C-Reactive Protein; Cardiac Rehabilitation; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation Mediators; Interleukin-1beta; Israel; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Time Factors; Treatment Outcome; Up-Regulation; Vildagliptin | 2017 |
The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dinoprost; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2017 |
The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3).
Topics: Adamantane; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin | 2017 |
Safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin and low-dose metformin.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2017 |
A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2
Topics: Adamantane; Adult; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Brazil; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2018 |
Vildagliptin Recruits Regulatory T Cells in Patients Undergoing Primary Percutaneous Coronary Intervention.
Topics: Adamantane; C-Reactive Protein; CD4 Lymphocyte Count; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Interferon-gamma; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Nitric Oxide; Nitriles; Percutaneous Coronary Intervention; Peroxidase; Pyrrolidines; Serum Albumin; T-Lymphocytes, Regulatory; Transforming Growth Factor beta1; Vildagliptin | 2018 |
Impact of treatment with glibenclamide or vildagliptin on glucose variability after aerobic exercise in type 2 diabetes: A randomized controlled trial.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exercise; Female; Glucose; Glyburide; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2018 |
Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nitriles; Prospective Studies; Pyrrolidines; Quality of Life; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2018 |
Role of endogenous glucagon-like peptide-1 enhanced by vildagliptin in the glycaemic and energy expenditure responses to intraduodenal fat infusion in type 2 diabetes.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Energy Metabolism; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Insulin; Nitriles; Pyrrolidines; Vildagliptin | 2020 |
Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes: The VILDDIAL study, a randomized, multicentre, prospective study.
Topics: Adamantane; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Renal Dialysis; Vildagliptin | 2020 |
Comparison of the Efficacy, Tolerability and Side Effect Profile of Vildagliptin-Metformin with Metformin-GlibenclamideMamong Nigerian.
Topics: Adamantane; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Metformin; Nigeria; Nitriles; Prospective Studies; Pyrrolidines; Vildagliptin | 2021 |
270 other study(ies) available for adamantane and vildagliptin
| Article | Year |
|---|---|
Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).
Topics: Adamantane; Binding Sites; Caco-2 Cells; Dipeptidyl Peptidase 4; Humans; Kinetics; Nitriles; Protease Inhibitors; Pyrrolidines; Structure-Activity Relationship; Substrate Specificity; Vildagliptin | 2005 |
Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.
Topics: Adamantane; Animals; Area Under Curve; Blood Glucose; Dietary Fats; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Oxidase; Glucose Tolerance Test; Insulin Resistance; Male; Nitriles; Pyrrolidines; Rats; Rats, Zucker; Tachyphylaxis; Time Factors; Vildagliptin; Weight Gain | 2005 |
American Diabetes Association - 65th Scientific Sessions. DDP-IV inhibitors.
Topics: Adamantane; Animals; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Humans; Islets of Langerhans; Nitriles; Peptide Fragments; Protease Inhibitors; Protein Precursors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin; Xanthines | 2005 |
Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice.
Topics: Adamantane; Animals; Body Weight; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Genotype; Glucose; Glucose Tolerance Test; Hepatocyte Nuclear Factor 1-alpha; In Vitro Techniques; Insulin; Insulin Secretion; Insulin-Secreting Cells; Intubation, Gastrointestinal; Male; Mice; Mice, Inbred CBA; Mice, Inbred Strains; Mice, Transgenic; Nitriles; Pyrrolidines; Time Factors; Vildagliptin | 2005 |
Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form.
Topics: Adamantane; Atrial Natriuretic Factor; Dipeptides; Dipeptidyl Peptidase 4; Humans; Hydrolysis; In Vitro Techniques; Kinetics; Natriuretic Peptide, Brain; Neprilysin; Nitriles; Peptide Fragments; Protease Inhibitors; Pyrrolidines; Vildagliptin | 2006 |
Molecule of the month. Vildagilptin.
Topics: Adamantane; Diabetes Mellitus; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin Resistance; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Vildagliptin | 2006 |
American Diabetes Association--66th scientific sessions. 9-13 June 2006, Washington, DC, USA.
Topics: Adamantane; Clinical Trials as Topic; Glucagon-Like Peptide 1; Humans; Liraglutide; Nitriles; Peripheral Vascular Diseases; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Dose-Response Relationship, Drug; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Tolerance Test; Hypoglycemic Agents; Imidazoles; Insulin; Kinetics; Mice; Mice, Inbred C57BL; Nitriles; Piperazines; Protease Inhibitors; Purines; Pyridazines; Pyrrolidines; Rats; Rats, Zucker; Tosyl Compounds; Vildagliptin | 2006 |
Oral agents for type 2 diabetes reduce HbA1c, are weight neutral.
Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.
Topics: Adamantane; Animals; Body Composition; Body Weight; Candy; Energy Intake; Energy Metabolism; Glucagon-Like Peptide 1; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Pancreas; Pyrrolidines; Rats; Rats, Sprague-Dawley; Vildagliptin | 2007 |
3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Amides; Aniline Compounds; Animals; Benzylamines; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Inhibitory Concentration 50; Nitriles; Phenethylamines; Pyrrolidines; Rats; Rats, Wistar; Structure-Activity Relationship; Vildagliptin | 2007 |
Gliptins.
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Neuropeptide Y; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
Dipeptidyl peptidase 8/9-like activity in human leukocytes.
Topics: Adamantane; Antibodies, Monoclonal; Dipeptidases; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Enzyme Activation; Humans; Indoles; Isoleucine; Leukocytes; Molecular Conformation; Nitriles; Organophosphonates; Piperidines; Proline; Protease Inhibitors; Pyrrolidines; Stereoisomerism; Structure-Activity Relationship; Vildagliptin | 2007 |
DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.
Topics: Adamantane; Amyloid; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Immunohistochemistry; Insulin; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Islets of Langerhans; Mice; Mice, Transgenic; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
New treatments for diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glipizide; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin | 2007 |
Which patients are candidates for dipeptidyl peptidase IV inhibitors?
Topics: Adamantane; Ambulatory Care; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Humans; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
Topics: Adamantane; Animals; Appetite; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.
Topics: Adamantane; Animals; Blood Glucose; Cell Division; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Mice; Nitriles; Pyrrolidines; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Receptors, Peptide; Vildagliptin | 2007 |
The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.
Topics: Adamantane; Administration, Oral; Adult; Aged; Aged, 80 and over; Aging; Body Mass Index; Female; Humans; Male; Nitriles; Pyrrolidines; Sex Characteristics; Vildagliptin | 2008 |
[Two breakthroughs in the treatment of type 2 diabetes. Both the receptor agonist and enzyme inhibitors now available in the clinic].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Nitriles; Peptides; Pyrrolidines; Receptors, Glucagon; Treatment Outcome; Venoms; Vildagliptin | 2007 |
Islet cell function is as interesting as insulin resistance for T2DM treatment options.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Insulin Resistance; Islets of Langerhans; Nitriles; Pyrrolidines; Vildagliptin | 2008 |
Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidases; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Female; Humans; Male; Mice; Mice, Inbred Strains; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Recombinant Proteins; Toxicity Tests; Vildagliptin | 2008 |
Three new drugs for type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2008 |
Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
Topics: Adamantane; Animals; Consciousness; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Glucagon; Glucagon-Like Peptide 1; Glucose; Insulin; Liver; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma.
Topics: Adamantane; Amyloid; Animals; Collagen; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Heart Ventricles; Humans; Kinetics; Nitriles; Organophosphonates; Peptide Fragments; Proline; Pyrrolidines; Rats; Rats, Wistar; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Substrate Specificity; Vildagliptin | 2009 |
[Future therapeutic options and their indications: transplantation and the possibilities of regenerative therapy for diabetes type 1].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 1; Exenatide; Humans; Insulin-Secreting Cells; Islets of Langerhans; Islets of Langerhans Transplantation; Mice; Nitriles; Peptides; Pyrazines; Pyrrolidines; Regeneration; Sitagliptin Phosphate; Stem Cell Transplantation; Transplantation, Heterologous; Triazoles; Venoms; Vildagliptin | 2008 |
Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
Topics: Absorption; Adamantane; Area Under Curve; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hydrolysis; Hypoglycemic Agents; In Vitro Techniques; Mass Spectrometry; Nitriles; Protein Binding; Pyrrolidines; Vildagliptin | 2009 |
Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs.
Topics: Adamantane; Animals; Area Under Curve; Biological Availability; Chromatography, High Pressure Liquid; Dipeptidyl-Peptidase IV Inhibitors; Dogs; In Vitro Techniques; Male; Nitriles; Protein Binding; Pyrrolidines; Rats; Rats, Inbred F344; Tandem Mass Spectrometry; Tissue Distribution; Vildagliptin | 2009 |
Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drugs, Investigational; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Treatment Outcome; Triazoles; Vildagliptin | 2009 |
ASP4000, a slow-binding dipeptidyl peptidase 4 inhibitor, has antihyperglycemic activity of long duration in Zucker fatty rats.
Topics: Adamantane; Animals; Azabicyclo Compounds; Blood Glucose; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Male; Nitriles; Pyrrolidines; Rats; Rats, Sprague-Dawley; Rats, Zucker; Recombinant Proteins; Vildagliptin | 2010 |
Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus.
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Nitriles; Pyrrolidines; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vildagliptin; Weight Gain | 2009 |
Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
[Vildagliptin (Galvus) and fixed combination vildagliptine-metformin (Eucreas) in the treatment of type 2 diabetes].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2009 |
Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema.
Topics: Adamantane; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Humans; Models, Biological; Nitriles; Pyrrolidines; Risk Factors; Vildagliptin | 2009 |
Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema.
Topics: Adamantane; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Humans; Meta-Analysis as Topic; Nitriles; Pyrrolidines; Risk Factors; Vildagliptin | 2009 |
Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein.
Topics: Adamantane; Adult; Chromatography, Liquid; Female; Humans; Kinetics; Male; Mass Spectrometry; Neuropeptide Y; Nitriles; Peptide Fragments; Peptides; Plasma Kallikrein; Protease Inhibitors; Protein Structure, Tertiary; Pyrrolidines; Substrate Specificity; Vildagliptin | 2009 |
Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.
Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2009 |
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2009 |
Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs.
Topics: Adamantane; Amines; Animals; Cattle; Dipeptidyl-Peptidase IV Inhibitors; Drug Stability; Humans; Nitriles; Oligopeptides; Prodrugs; Pyrrolidines; Solubility; Structure-Activity Relationship; Vildagliptin | 2010 |
Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gerbillinae; Glucagon-Like Peptide 1; Immunohistochemistry; Insulin; Liraglutide; Male; Nitriles; Pancreas; Pyrrolidines; Reference Standards; Vildagliptin | 2010 |
Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Eating; Electric Stimulation; Epidermis; Glucagon-Like Peptide 1; Humans; Insulin; Male; Nerve Degeneration; Nitriles; Peripheral Nerves; Pyrrolidines; Random Allocation; Rats; Rats, Sprague-Dawley; Ubiquitin Thiolesterase; Vildagliptin | 2009 |
Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.
Topics: Adamantane; Animals; Cells, Cultured; Cellular Senescence; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; DNA Damage; Dose-Response Relationship, Drug; Endothelial Cells; Enzyme Activation; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Heme Oxygenase-1; Humans; Hydrogen Peroxide; Hypoglycemic Agents; Male; NAD(P)H Dehydrogenase (Quinone); Nitriles; Oxidants; Oxidative Stress; Peptides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrrolidines; Rats; Rats, Zucker; Reactive Oxygen Species; Receptors, Glucagon; Signal Transduction; Venoms; Vildagliptin | 2010 |
[New hypoglycemic agents in type 2 diabetes].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2010 |
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials.
Topics: Adamantane; Aged; Clinical Trials as Topic; Confidence Intervals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Immune System; Liver; Male; Nitriles; Pancreas; Pyrrolidines; Risk Factors; Skin; Vildagliptin | 2010 |
Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats.
Topics: Adamantane; Animals; Blood Glucose; Cyclohexanes; Drug Therapy, Combination; Fatty Acids; Forkhead Transcription Factors; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liver; Male; Metabolic Diseases; Nateglinide; Nerve Tissue Proteins; Nitriles; Organ Size; Phenylalanine; Phosphorylation; Postprandial Period; Pyrrolidines; Rats; Rats, Zucker; Triglycerides; Vildagliptin | 2010 |
Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study.
Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Drug Tolerance; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney Function Tests; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Retrospective Studies; Safety; Thiazolidinediones; Vildagliptin | 2010 |
Multidrug therapy in a patient with Rabson-Mendenhall syndrome.
Topics: Adamantane; Adolescent; Diabetes Mellitus, Type 2; Donohue Syndrome; Humans; Hypoglycemic Agents; Male; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Vildagliptin | 2010 |
Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats.
Topics: Adamantane; Administration, Oral; Animals; Chromatography, Liquid; Dipeptidyl-Peptidase IV Inhibitors; Male; Mass Spectrometry; Nitriles; Pyrrolidines; Rats; Rats, Sprague-Dawley; Thioctic Acid; Vildagliptin | 2010 |
The dipeptidyl peptidase IV (CD26, EC 3.4.14.5) inhibitor vildagliptin is a potent antihyperalgesic in rats by promoting endomorphin-2 generation in the spinal cord.
Topics: Adamantane; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Hyperalgesia; Injections, Spinal; Injections, Subcutaneous; Male; Nitriles; Oligopeptides; Pyrrolidines; Rats; Rats, Wistar; Reproducibility of Results; Spinal Cord; Time Factors; Vildagliptin | 2011 |
The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats.
Topics: Adamantane; Animals; Animals, Newborn; Apoptosis; Cell Proliferation; Dipeptidyl-Peptidase IV Inhibitors; Insulin-Secreting Cells; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Vildagliptin | 2011 |
[Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose Intolerance; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Islets of Langerhans; Nitriles; Pyrrolidines; Vildagliptin | 2010 |
Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials.
Topics: Adamantane; Aged; Aged, 80 and over; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Nitriles; Polypharmacy; Pyrrolidines; Treatment Outcome; Vildagliptin | 2011 |
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin | 2011 |
Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis.
Topics: Adamantane; Animals; Aorta, Thoracic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycation End Products, Advanced; Male; Nitriles; Obesity; Pyrrolidines; Rats; Rats, Inbred OLETF; Vascular System Injuries; Vildagliptin | 2011 |
Dipeptidyl peptidase IV dependent water-soluble prodrugs of highly lipophilic bicyclic nucleoside analogues.
Topics: Adamantane; Administration, Oral; Animals; Antiviral Agents; Biological Availability; Caco-2 Cells; Cattle; Dipeptidyl-Peptidase IV Inhibitors; Drug Stability; Female; Furans; Herpesvirus 3, Human; Heterocyclic Compounds, 2-Ring; Humans; Hydrolysis; Mice; Nitriles; Nucleosides; Oligopeptides; Prodrugs; Pyrimidines; Pyrrolidines; Solubility; Structure-Activity Relationship; Vildagliptin; Water | 2011 |
Understanding the incretin effect.
Topics: Adamantane; Animals; Blood Glucose; Comprehension; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Incretins; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Vildagliptin | 2011 |
Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
Topics: Adamantane; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Gliclazide; Humans; Hypoglycemic Agents; Islam; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Time Factors; Vildagliptin | 2011 |
Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs.
Topics: Adamantane; Animals; Bombesin; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Nitriles; Peptide Fragments; Portal Vein; Pyrrolidines; Swine; Vildagliptin | 2011 |
Effectiveness of adding vildagliptin to the treatment of diabetic patients nonresponsive to the combination of metformin and a sulphonylurea.
Topics: Adamantane; Administration, Oral; Adult; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Time Factors; Treatment Failure; Treatment Outcome; Vildagliptin | 2011 |
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2011 |
Stability and bioactivity studies on dipeptidyl peptidase IV resistant glucogan-like peptide-1 analogues.
Topics: Adamantane; Animals; Dipeptidyl Peptidase 4; Drug Combinations; Drug Evaluation, Preclinical; Drug Stability; Glucagon-Like Peptide 1; Glucose Tolerance Test; Half-Life; Hypoglycemic Agents; Male; Mice; Nitriles; Protein Processing, Post-Translational; Proteolysis; Pyrrolidines; Structure-Activity Relationship; Vildagliptin | 2012 |
Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222.
Topics: Adamantane; Amides; Blood Proteins; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Dibenzocycloheptenes; Dipeptidyl-Peptidase IV Inhibitors; Drug Delivery Systems; Humans; Inhibitory Concentration 50; Kinetics; Nitriles; Protein Binding; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Tetrazoles; Time Factors; Triazoles; Ultracentrifugation; Vildagliptin | 2011 |
Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.
Topics: Adamantane; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Administration Schedule; Heart Failure; Male; Myocardial Infarction; Nitriles; Pyrrolidines; Random Allocation; Rats; Rats, Sprague-Dawley; Time Factors; Vildagliptin | 2011 |
Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy.
Topics: Adamantane; Animals; Behavior, Animal; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Dose-Response Relationship, Drug; Drinking; Eating; Glucagon-Like Peptide 1; Glucose Tolerance Test; Male; Neural Conduction; Nitriles; Pain Threshold; Peripheral Nervous System Diseases; Pyrrolidines; Rats; Rats, Sprague-Dawley; Sodium-Potassium-Exchanging ATPase; Vildagliptin | 2012 |
Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin.
Topics: Adamantane; Animals; Blood Glucose; Calcium; Cardiac Output; Cytokines; Cytosol; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Hemodynamics; Insulin; Insulin-Secreting Cells; Nitric Oxide; Nitriles; Peroxynitrous Acid; Pyrrolidines; Rats; Rats, Wistar; Regional Blood Flow; Vildagliptin | 2012 |
CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation.
Topics: Adamantane; Animals; Antigens, CD34; Chemokine CXCL12; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Hematopoietic Stem Cells; Injections, Subcutaneous; Lung; Lung Transplantation; Male; Mice; Mice, Inbred C57BL; Nitriles; Pyrrolidines; Receptors, CXCR4; Reperfusion Injury; Vildagliptin | 2012 |
Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury.
Topics: Adamantane; Animals; Cardiotonic Agents; Dipeptidyl-Peptidase IV Inhibitors; Male; Mitochondria, Heart; Myocardial Reperfusion Injury; Nitriles; Pyrrolidines; Random Allocation; Rats; Rats, Wistar; Swine; Vildagliptin | 2013 |
Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and β-cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet.
Topics: Adamantane; Animal Feed; Animals; Apoptosis; Bromodeoxyuridine; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Glucose Tolerance Test; Insulin Receptor Substrate Proteins; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Nitriles; Pyrrolidines; Time Factors; Vildagliptin | 2012 |
Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.
Topics: Adamantane; Algorithms; Animals; Artifacts; Cloning, Molecular; Dipeptidases; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Indicators and Reagents; Kinetics; Macaca fascicularis; Nitriles; Protein Binding; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Species Specificity; Triazoles; Vildagliptin | 2012 |
Stability-indicating RP-LC method for the determination of vildagliptin and mass spectrometry detection for a main degradation product.
Topics: Adamantane; Chromatography, Reverse-Phase; Dipeptidyl-Peptidase IV Inhibitors; Drug Stability; Hydrolysis; Limit of Detection; Linear Models; Nitriles; Oxidation-Reduction; Pharmaceutical Preparations; Pyrrolidines; Tablets; Vildagliptin | 2012 |
Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats.
Topics: Adamantane; Animals; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Male; Nitriles; Oxidative Stress; Pyrrolidines; Rats; Rats, Sprague-Dawley; Vildagliptin | 2012 |
Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Heart Diseases; Heart Rate; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Vildagliptin | 2012 |
DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury.
Topics: Adamantane; Animals; Apoptosis; Blood Glucose; Creatinine; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Kidney; Kidney Tubules; Male; Nitriles; Oxidative Stress; Pyrrolidines; Rats; Reperfusion Injury; Vildagliptin | 2012 |
[Therapeutic use and adverse events of incretin-related drugs].
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2012 |
Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-γ expression.
Topics: 3T3-L1 Cells; Adamantane; Adipocytes; Animals; Cell Differentiation; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression; Insulin; Lipid Metabolism; Mice; Neuropeptide Y; Nitriles; PPAR gamma; Proteolysis; Pyrrolidines; Receptors, Neuropeptide Y; Vildagliptin | 2012 |
Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adamantane; Animals; Apoptosis; Cell Proliferation; Deoxyguanosine; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Eating; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Nitriles; Pyrrolidines; Rats; Time Factors; Vildagliptin | 2012 |
DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice.
Topics: Adamantane; Animals; Blood Glucose; CCAAT-Enhancer-Binding Protein-beta; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Endoplasmic Reticulum Stress; Exenatide; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Hyperglycemia; Insulin; Insulin-Secreting Cells; Leupeptins; Mice; Mice, Transgenic; Nitriles; Peptides; Pyrrolidines; Venoms; Vildagliptin | 2012 |
Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man.
Topics: Adamantane; Animals; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Islets of Langerhans; Male; Mice; Mice, Transgenic; Nitriles; Pancreas, Exocrine; Pancreatic Neoplasms; Pancreatitis; Predictive Value of Tests; Pyrrolidines; Rats; Rats, Transgenic; Rats, Wistar; Vildagliptin | 2013 |
Vildagliptin preserves the mass and function of pancreatic β cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes.
Topics: Adamantane; Animals; Apoptosis; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Experimental; Endoplasmic Reticulum Stress; Gene Expression Regulation, Developmental; Immunohistochemistry; Insulin; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Nitriles; Oxidative Stress; Pyrrolidines; Real-Time Polymerase Chain Reaction; Triglycerides; Up-Regulation; Vildagliptin | 2013 |
Factors associated with the glucose-lowering effect of vildagliptin identified from the results of the oral glucose tolerance test in Japanese patients with type 2 diabetes.
Topics: Adamantane; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Japan; Male; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2013 |
A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Nitriles; Pyrazines; Pyrazoles; Pyrrolidines; Rats; Rats, Wistar; Rats, Zucker; Sitagliptin Phosphate; Thiazolidines; Triazoles; Vildagliptin | 2012 |
Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4.
Topics: Adamantane; Animals; Dipeptidyl Peptidase 4; Eating; Gene Deletion; Gene Expression Regulation; Glucagon-Like Peptide-1 Receptor; Heterozygote; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Models, Biological; Nitriles; Pyrrolidines; Rats; Rats, Long-Evans; Receptors, Glucagon; Vildagliptin | 2012 |
Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory Activity.
Topics: Acetylcholine; Adamantane; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Blood Pressure; Blotting, Western; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; E-Selectin; Egg Proteins; Endothelium, Vascular; Immunohistochemistry; In Vitro Techniques; Kidney; Nitriles; Peptidyl-Dipeptidase A; Prostaglandin-Endoperoxide Synthases; Protein Hydrolysates; Pyrrolidines; Rats; Rats, Inbred SHR; Rats, Zucker; Reverse Transcriptase Polymerase Chain Reaction; Vasodilation; Vasodilator Agents; Vildagliptin | 2012 |
Acute assessment of an aspalathin-enriched green rooibos (Aspalathus linearis) extract with hypoglycemic potential.
Topics: Adamantane; Animals; Aspalathus; Blood Glucose; Cell Line; Chalcones; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Glucose Tolerance Test; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Male; Nitriles; Phytotherapy; Plant Extracts; Pyrrolidines; Rats; Rats, Wistar; Rutin; Vildagliptin | 2012 |
Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucagon-Like Peptide 1; Humans; Incretins; Kidney Failure, Chronic; Liraglutide; Magnetic Resonance Imaging; Male; Nitriles; Pancreatitis; Pyrrolidines; Renal Dialysis; Tomography, X-Ray Computed; Vildagliptin | 2012 |
DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption.
Topics: Adamantane; Animals; Brain; Cognition; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression; Glucagon-Like Peptide 1; Insulin Receptor Substrate Proteins; Insulin Resistance; Long-Term Synaptic Depression; Male; Maze Learning; Membrane Potential, Mitochondrial; Memory; Mitochondria; Neurons; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrrolidines; Rats; Rats, Wistar; Receptor, Insulin; Vildagliptin | 2013 |
Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease.
Topics: Adamantane; Aged; Carbamates; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Ischemic Preconditioning; Male; Middle Aged; Nitriles; Piperidines; Prospective Studies; Pyrrolidines; Vildagliptin | 2013 |
Marked improvement of elderly postprandial hypotension by dipeptidyl peptidase IV inhibitor.
Topics: Adamantane; Aged, 80 and over; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypotension; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin | 2013 |
Acute necrotizing pancreatitis associated with vildagliptin.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Male; Middle Aged; Nitriles; Pancreatitis, Acute Necrotizing; Pyrrolidines; Vildagliptin | 2013 |
Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
Topics: Adamantane; Aged; Angioedema; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Substitution; Humans; Male; Nitriles; Piperidines; Pyrrolidines; Uracil; Vildagliptin | 2013 |
Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.
Topics: Adamantane; Albuminuria; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diastole; Drug Therapy, Combination; Fasting; Hypoglycemic Agents; Male; Nitriles; Pyrrolidines; Rats, Wistar; Systole; Telmisartan; Vildagliptin | 2014 |
A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors.
Topics: Adamantane; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Male; Middle Aged; Nitriles; Pemphigoid, Bullous; Pyrrolidines; Severity of Illness Index; Vildagliptin | 2013 |
Effects of vildagliptin/metformin therapy on patient-reported outcomes: work productivity, patient satisfaction, and resource utilization.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Combinations; Efficiency; Employment; Female; Health Care Costs; Health Services; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Nitriles; Patient Satisfaction; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin | 2013 |
Quantitative structure-activity relationship models of clinical pharmacokinetics: clearance and volume of distribution.
Topics: Adamantane; Biological Availability; Computer Simulation; Dipeptidyl-Peptidase IV Inhibitors; Half-Life; Humans; Injections, Intravenous; Linear Models; Models, Statistical; Nitriles; Pharmacokinetics; Pyrrolidines; Quantitative Structure-Activity Relationship; Support Vector Machine; Vildagliptin | 2013 |
DPP4 inhibitor-induced polyarthritis: a report of three cases.
Topics: Adamantane; Arthritis; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2014 |
Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.
Topics: Adamantane; Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiotonic Agents; Cholesterol; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Heart; Heart Rate; Insulin; Insulin Resistance; Male; Malondialdehyde; Membrane Potential, Mitochondrial; Mitochondria, Heart; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats, Wistar; Reactive Oxygen Species; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site.
Topics: Adamantane; Catalytic Domain; Crystallography, X-Ray; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Multiprotein Complexes; Nitriles; Oligopeptides; Piperidines; Protein Binding; Protein Interaction Mapping; Pyrazines; Pyrazoles; Pyrrolidines; Serine; Sitagliptin Phosphate; Structure-Activity Relationship; Thiazolidines; Triazoles; Uracil; Vildagliptin; X-Ray Diffraction | 2013 |
Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice.
Topics: Adamantane; Animals; Apoptosis; Blood Pressure; Blotting, Western; Dipeptidyl-Peptidase IV Inhibitors; Electrocardiography; Enzyme-Linked Immunosorbent Assay; Fibrosis; Glucagon-Like Peptide 1; Glucose Tolerance Test; Heart Failure; Heart Rate; Hemodynamics; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred C57BL; Nitriles; Organ Size; Pyrrolidines; Real-Time Polymerase Chain Reaction; Survival; Vildagliptin | 2013 |
Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
Topics: Adamantane; Animals; Antioxidants; Biomarkers; Blood Glucose; Body Weight; Catalase; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Incretins; Insulin; Insulin-Secreting Cells; Nitriles; Oxidation-Reduction; Oxidative Stress; Pyrrolidines; Rats; Streptozocin; Superoxide Dismutase; Vildagliptin | 2013 |
DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats.
Topics: Adamantane; Animals; Behavior, Animal; Brain; Cognition Disorders; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Hippocampus; Insulin Resistance; Male; Maze Learning; Memory; Memory Disorders; Mitochondria; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Heart Transplantation; Humans; Immunosuppressive Agents; Lipids; Male; Middle Aged; Nitriles; Pyrrolidines; Retrospective Studies; Vildagliptin | 2013 |
Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Female; Immunohistochemistry; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Nitriles; Obesity; Pyrrolidines; Vildagliptin | 2013 |
Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fasting; Female; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Medication Adherence; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2013 |
Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction.
Topics: Adamantane; Animals; Cell Survival; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Heart; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Individualising treatment for older people with diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Nitriles; Pyrrolidines; Vildagliptin | 2013 |
Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes.
Topics: Adamantane; Blood Glucose; Body Mass Index; C-Peptide; Creatinine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Insulin Resistance; Male; Middle Aged; Multivariate Analysis; Nitriles; Pyrazines; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
The effects of dipeptidyl-peptidase-IV inhibitor, vildagliptin, on the exocrine pancreas in spontaneously diabetic Goto-Kakizaki rats.
Topics: Acinar Cells; Adamantane; Animals; Apoptosis; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Glucagon-Like Peptide 1; Immunohistochemistry; Insulin; Ki-67 Antigen; Male; Nitriles; Pancreas, Exocrine; Pancreatic Ducts; Pyrrolidines; Rats; Rats, Wistar; Species Specificity; Vildagliptin | 2013 |
Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment.
Topics: Adamantane; Adult; Aged; Area Under Curve; Body Mass Index; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Nitriles; Pyrrolidines; Renal Insufficiency; Vildagliptin | 2013 |
Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glyburide; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Vildagliptin | 2013 |
Cognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes.
Topics: Adamantane; Aged; Aged, 80 and over; Cognition; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Nitriles; Prospective Studies; Pyrrolidines; Vildagliptin | 2013 |
Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study.
Topics: Adamantane; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; India; Metformin; Nitriles; Obesity; Postprandial Period; Pyrrolidines; Retrospective Studies; Treatment Outcome; Vildagliptin | 2014 |
[Case report; suspected DPP-4 inhibitor-induced dropped head syndrome].
Topics: Adamantane; Aged, 80 and over; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Humans; Male; Neck; Neck Muscles; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2013 |
Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE).
Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Vildagliptin | 2013 |
Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice.
Topics: Adamantane; Alternative Splicing; Animals; Apolipoproteins E; Atherosclerosis; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Foam Cells; Gene Expression Profiling; Gene Expression Regulation; Gene Order; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Incretins; Macrophages; Male; Mice; Mice, Inbred NOD; Mice, Knockout; Nitriles; Pyrrolidines; Receptors, Glucagon; Vildagliptin | 2013 |
The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Medication Adherence; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin; Weight Loss | 2013 |
Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Kidney; Male; Nitriles; Proteinuria; Pyrrolidines; Random Allocation; Rats; Rats, Zucker; Renal Circulation; Sclerosis; Vasoconstriction; Vildagliptin | 2014 |
Ramadan: type 2 diabetes and risk of hypoglycaemia.
Topics: Adamantane; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hypoglycemic Agents; Islam; Male; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2013 |
Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats.
Topics: Adamantane; Administration, Oral; Analysis of Variance; Animals; Biomarkers; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression Profiling; Male; Nitriles; Obesity; Pyrrolidines; Rats; Real-Time Polymerase Chain Reaction; Retina; Vildagliptin | 2013 |
Development of validated stability indicating assay method for simultaneous estimation of metformin hydrochloride and vildagliptin by RP-HPLC.
Topics: Adamantane; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Dipeptidyl-Peptidase IV Inhibitors; Drug Stability; Hypoglycemic Agents; Limit of Detection; Metformin; Nitriles; Pyrrolidines; Quality Control; Reproducibility of Results; Sensitivity and Specificity; Tablets; Vildagliptin | 2014 |
Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucose Tolerance Test; Hypoglycemic Agents; Islets of Langerhans; Male; Mice; Mice, Inbred Strains; Nitriles; Pyrrolidines; Vildagliptin | 2013 |
Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease.
Topics: Adamantane; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition Disorders; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hippocampus; Hypoglycemic Agents; Interleukin-1beta; Male; Maze Learning; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Streptozocin; tau Proteins; Tumor Necrosis Factor-alpha; Vildagliptin | 2013 |
Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.
Topics: Adamantane; Animals; Cyclic AMP-Dependent Protein Kinases; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Heart; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitriles; Pyrazines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Glucagon; Severity of Illness Index; Signal Transduction; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Benchmarking in vitro covalent binding burden as a tool to assess potential toxicity caused by nonspecific covalent binding of covalent drugs.
Topics: Adamantane; Aspirin; Carbon Radioisotopes; Cells, Cultured; Drug-Related Side Effects and Adverse Reactions; Glutathione; Half-Life; Hepatocytes; Humans; Lactones; Lysine; Nitriles; Orlistat; Pharmaceutical Preparations; Pyrrolidines; Tritium; Vildagliptin | 2013 |
Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme.
Topics: Acyclovir; Adamantane; Animals; Antiviral Agents; Biocatalysis; Cattle; Cells, Cultured; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Fibroblasts; Herpesvirus 1, Human; Herpesvirus 2, Human; Humans; Hydrolysis; Microbial Sensitivity Tests; Nitriles; Prodrugs; Pyrrolidines; Solubility; Structure-Activity Relationship; Vildagliptin; Water | 2013 |
Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
Topics: Adamantane; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Homeodomain Proteins; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Nitriles; Phlorhizin; Pyrrolidines; Tetrazoles; Trans-Activators; Valine; Valsartan; Vildagliptin | 2013 |
Natural products for Alzheimer's disease therapy: basic and application.
Topics: Adamantane; Alzheimer Disease; Animals; Berberis; Biological Products; Cholinesterase Inhibitors; Drugs, Chinese Herbal; Humans; Nitriles; Phytotherapy; Pyrrolidines; Structure-Activity Relationship; Vildagliptin | 2013 |
The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses.
Topics: Adamantane; Adaptive Immunity; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Immunity, Innate; Mice; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; T-Lymphocytes; Triazoles; Vildagliptin | 2014 |
Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Germany; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2014 |
Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia-reperfusion rat heart.
Topics: Adamantane; Animals; Apoptosis; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Male; Mitochondria; Myocardial Ischemia; Myocardial Reperfusion Injury; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Vildagliptin | 2014 |
Pharmacoeconomic analysis of DPP-4 inhibitors.
Topics: Adamantane; Clinical Trials as Topic; Cohort Studies; Cost-Benefit Analysis; Costs and Cost Analysis; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels.
Topics: 1-Deoxynojirimycin; Adamantane; Adult; Blood Glucose; Cholecystokinin; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Ghrelin; Humans; Insulin; Male; Middle Aged; Nitriles; Peptide YY; Pyrrolidines; Vildagliptin | 2014 |
Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV.
Topics: Adamantane; Administration, Oral; Animals; Caco-2 Cells; Crystallography, X-Ray; Cyclization; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Discovery; Enzyme Activation; Humans; Inhibitory Concentration 50; Methylamines; Molecular Structure; Nitriles; Pyrazines; Pyrrolidines; Rats; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2014 |
Vascular origin of vildagliptin-induced skin effects in Cynomolgus monkeys: pathomechanistic role of peripheral sympathetic system and neuropeptide Y.
Topics: Adamantane; Administration, Oral; Animals; Blood Pressure; Cold Temperature; Dipeptidases; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Macaca fascicularis; Neuropeptide Y; Nitriles; Norepinephrine; Pyrrolidines; Skin; Skin Diseases; Stress, Physiological; Vascular System Injuries; Vasoconstriction; Vildagliptin | 2014 |
[Not Available].
Topics: Adamantane; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Nitriles; Pyrrolidines; Vildagliptin | 2013 |
Adding a DPP-4 inhibitor to metformin therapy may be safer than you think.
Topics: Adamantane; Diabetes Mellitus, Type 2; Female; Humans; Male; Metformin; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2014 |
Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats.
Topics: Adamantane; Adrenergic beta-Agonists; Animals; Cardiomegaly; Dipeptidyl-Peptidase IV Inhibitors; Male; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Treatment Outcome; Vildagliptin | 2014 |
Validation of different spectrophotometric methods for determination of vildagliptin and metformin in binary mixture.
Topics: Adamantane; Limit of Detection; Metformin; Nitriles; Pyrrolidines; Reference Standards; Spectrophotometry; Tablets; Vildagliptin | 2014 |
Capillary zone electrophoresis for determination of vildagliptin (a DPP-4 inhibitor) in pharmaceutical formulation and comparative study with HPLC.
Topics: Adamantane; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Dipeptidyl-Peptidase IV Inhibitors; Electrophoresis, Capillary; Indicators and Reagents; Limit of Detection; Nitriles; Pyrrolidines; Reference Standards; Reproducibility of Results; Solutions; Tablets; Vildagliptin | 2014 |
Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
Topics: Adamantane; Computer Simulation; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Economic; Nitriles; Portugal; Prospective Studies; Pyrrolidines; Quality-Adjusted Life Years; Risk Factors; Sulfonylurea Compounds; Vildagliptin | 2014 |
Validation of LC-MS/MS method applied to evaluation of free tissue concentrations of vildagliptin in diabetic rats by microdialysis.
Topics: Adamantane; Animals; Chromatography, High Pressure Liquid; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Drug Stability; Liver; Male; Microdialysis; Muscles; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Tissue Distribution; Vildagliptin | 2014 |
Between reduction of glucose fluctuations and increased therapeutic adherence: an example of the benefits of vildagliptin in an elderly diabetic patient.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Medication Adherence; Nitriles; Pyrrolidines; Vildagliptin | 2015 |
Is there an impact of treatment with DPP-4 inhibitors on lymphocyte subpopulations in type 2 diabetic patients?
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Lymphocyte Subsets; Male; Middle Aged; Nitriles; Pyrrolidines; Random Allocation; Sitagliptin Phosphate; Vildagliptin | 2014 |
Effectiveness and tolerability of second-line therapy with vildagliptin versus other oral agents in type 2 diabetes (EDGE): post-hoc subanalysis of the Belgian data.
Topics: Adamantane; Administration, Oral; Aged; Belgium; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2014 |
Bullous pemphigoid induced by vildagliptin: a report of three cases.
Topics: Adamantane; Aged; Aged, 80 and over; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Nitriles; Pemphigoid, Bullous; Pyrrolidines; Vildagliptin | 2015 |
Comparative effectiveness of vildagliptin in combination with other oral anti-diabetes agents in usual-care conditions: the EDGE-Latin America study.
Topics: Adamantane; Administration, Oral; Adult; Aged; Biomarkers; Comparative Effectiveness Research; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Latin America; Male; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin | 2014 |
Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Female; Glucose; Humans; Immunohistochemistry; Insulin; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Nitriles; Pyrrolidines; Vildagliptin | 2014 |
Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Nitriles; Pyrrolidines; Retrospective Studies; Vildagliptin | 2014 |
The dipeptidyl peptidase-4 inhibitor vildagliptin has the capacity to repair β-cell dysfunction and insulin resistance.
Topics: Adamantane; Area Under Curve; C-Reactive Protein; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2014 |
Human nitrilase-like protein does not catalyze the hydrolysis of vildagliptin.
Topics: Adamantane; Aminohydrolases; Animals; Biotransformation; Carboxylic Acids; Catalysis; Dipeptidyl-Peptidase IV Inhibitors; HEK293 Cells; Humans; Hydrolysis; Isoenzymes; Liver; Male; Mice, Inbred C57BL; Microsomes, Liver; Nitriles; Pyrrolidines; Substrate Specificity; Transfection; Vildagliptin | 2014 |
Simultaneous determination of metformin and vildagliptin in human plasma by a HILIC-MS/MS method.
Topics: Adamantane; Adult; Chromatography, Liquid; Drug Stability; Female; Humans; Hydrophobic and Hydrophilic Interactions; Limit of Detection; Linear Models; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Reproducibility of Results; Tandem Mass Spectrometry; Vildagliptin | 2014 |
Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats.
Topics: Adamantane; Animals; Arrhythmias, Cardiac; Calcium; Cardiotonic Agents; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Heart Rate; Insulin Resistance; Intracellular Space; Male; Metformin; Mitochondria; Myocardial Ischemia; Myocardial Reperfusion Injury; Nitriles; Obesity; Pyrrolidines; Rats; Rats, Wistar; Ventricular Dysfunction, Left; Vildagliptin | 2014 |
Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric-oxide synthase-dependent mechanism.
Topics: 3T3-L1 Cells; Adamantane; Adipocytes; Adiponectin; Animals; Cell Differentiation; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hindlimb; Human Umbilical Vein Endothelial Cells; Ischemia; Mice; Mice, Knockout; Muscle, Skeletal; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Nitriles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrrolidines; Signal Transduction; Vildagliptin | 2014 |
Idiosyncratic liver injury induced by vildagliptin with successful switch to linagliptin in a hemodialyzed diabetic patient.
Topics: Adamantane; Aged; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Linagliptin; Nitriles; Purines; Pyrrolidines; Quinazolines; Renal Dialysis; Vildagliptin | 2014 |
Vildagliptin in patients with type 2 diabetes mellitus and renal impairment.
Topics: Adamantane; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Male; Nitriles; Pyrrolidines; Renal Insufficiency; Vildagliptin | 2014 |
Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in association with its effects suppressing endoplasmic reticulum stress in db/db mice.
Topics: Activating Transcription Factor 4; Adamantane; Animals; Apoptosis; Caspase 3; Cell Cycle Proteins; Cell Nucleus; Cell Proliferation; Cell Survival; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Endoplasmic Reticulum Stress; Hyperglycemia; Insulin; Insulin-Secreting Cells; Male; Mice, Mutant Strains; Nitriles; Pyrrolidines; Random Allocation; Transcription Factor CHOP; Vildagliptin | 2015 |
Analgesic and anti-inflammatory effectiveness of sitagliptin and vildagliptin in mice.
Topics: Adamantane; Allyl Compounds; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Capsaicin; Disease Models, Animal; Dose-Response Relationship, Drug; Edema; Freund's Adjuvant; Isothiocyanates; Male; Mice; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Temperature; Urinary Bladder; Vildagliptin | 2014 |
DPP-4 inhibitor and PPARγ agonist restore the loss of CA1 dendritic spines in obese insulin-resistant rats.
Topics: Adamantane; Animals; Blood Glucose; Cholesterol; Dendritic Spines; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Hippocampus; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Neuroprotective Agents; Nitriles; Obesity; Pioglitazone; PPAR gamma; Pyrrolidines; Rats; Rats, Wistar; Receptor, Insulin; Thiazolidinediones; Vildagliptin | 2014 |
Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2014 |
[Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics].
Topics: Adamantane; Adult; Aged; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2014 |
Vildagliptin induces β-cell neogenesis and improves the lipid profile in a later phase of type 1 diabetes.
Topics: Adamantane; Animals; Blood Glucose; Cell Proliferation; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Female; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Lipid Metabolism; Nitriles; Pyrrolidines; Rats, Inbred F344; Triglycerides; Vildagliptin | 2015 |
Incretin therapy and beta cell function.
Topics: Adamantane; Animals; Apoptosis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Endoplasmic Reticulum Stress; Insulin-Secreting Cells; Male; Nitriles; Pyrrolidines; Vildagliptin | 2015 |
Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study.
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin | 2015 |
Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats.
Topics: Adamantane; Animals; Antihypertensive Agents; Arterial Pressure; Blood Pressure; Circadian Rhythm; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glucagon-Like Peptide 1; Heart Rate; Hypertension; Injections, Intraventricular; Male; Nitriles; Pyrrolidines; Rats; Rats, Inbred Dahl; Sodium; Sodium Chloride, Dietary; Telemetry; Vildagliptin | 2015 |
Dipeptidyl peptidase-4 greatly contributes to the hydrolysis of vildagliptin in human liver.
Topics: Adamantane; Animals; Biotransformation; Cytosol; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; HEK293 Cells; Humans; Hydrolysis; Liver; Male; Mice; Microsomes, Liver; Nitriles; Pyrrolidines; Rats, Inbred F344; Species Specificity; Transfection; Vildagliptin | 2015 |
Compatible validated spectrofluorimetric and spectrophotometric methods for determination of vildagliptin and saxagliptin by factorial design experiments.
Topics: Adamantane; Benzoquinones; Chloranil; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Limit of Detection; Nitriles; Pyrrolidines; Spectrometry, Fluorescence; Spectrophotometry; Tablets; Vildagliptin | 2015 |
Dipeptidyl peptidase 4 inhibitor reduces intimal hyperplasia in rabbit autologous jugular vein graft under poor distal runoff.
Topics: Adamantane; Administration, Oral; Animals; Autografts; Calcium; Calcium Signaling; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Glucagon-Like Peptide 1; Hyperplasia; Jugular Veins; Male; Neointima; Nitric Oxide; Nitric Oxide Synthase; Nitriles; Pyrrolidines; Time Factors; Vasodilation; Vasodilator Agents; Vildagliptin | 2016 |
DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice.
Topics: Adamantane; Animals; Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Gastric Inhibitory Polypeptide; Glucagon; Hypoglycemia; Mice; Mice, Knockout; Nitriles; Pyrrolidines; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Signal Transduction; Vildagliptin | 2015 |
Nanoparticle formulation by Büchi B-90 Nano Spray Dryer for oral mucoadhesion.
Topics: Adamantane; Adhesiveness; Administration, Oral; Drug Delivery Systems; Gelatin; Humans; Hypoglycemic Agents; Nanoparticles; Nitriles; Particle Size; Pyrrolidines; Surface Properties; Technology, Pharmaceutical; Vildagliptin | 2015 |
Development of miniaturized sorbent membrane funnel-based spray platform for biological analysis.
Topics: Adamantane; Amino Acid Sequence; Animals; Cattle; Humans; Membranes, Artificial; Miniaturization; Molecular Sequence Data; Nitriles; Phosphopeptides; Proteomics; Pyrrolidines; Serum Albumin, Bovine; Solid Phase Extraction; Titanium; Trypsin; Vildagliptin | 2015 |
Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study.
Topics: Adamantane; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Monitoring; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Turkey; Vildagliptin | 2015 |
Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study.
Topics: Adamantane; Adult; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Logistic Models; Male; Middle Aged; Middle East; Nitriles; Odds Ratio; Prevalence; Pyrrolidines; Time Factors; Treatment Outcome; Vildagliptin | 2015 |
Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways.
Topics: Adamantane; Animals; Antioxidants; Apoptosis; Dopamine; Hypoglycemic Agents; Male; Motor Activity; Neuroprotective Agents; NF-E2-Related Factor 2; NF-kappa B; Nitriles; Oxidative Stress; Parkinson Disease, Secondary; Pyrrolidines; Rats; Rats, Wistar; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Rotenone; Signal Transduction; Uncoupling Agents; Vildagliptin | 2015 |
Beneficial Effects of Vildagliptin on Metabolic Parameters in Patients with Type 2 Diabetes.
Topics: Adamantane; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Retrospective Studies; Treatment Outcome; Vildagliptin | 2015 |
Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction.
Topics: Adamantane; Angiotensin-Converting Enzyme Inhibitors; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Enalapril; Fibrosis; Heart Rate; Hypoglycemic Agents; Male; Metformin; Myocardial Infarction; Myocardium; Nitriles; Oxidative Stress; Pyrrolidines; Rats, Wistar; Recovery of Function; Signal Transduction; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling; Vildagliptin | 2015 |
Comparison of hypoglycaemia episodes in people with type-2 diabetes fasting in Ramazan, treated with vildaglipton or sulphonylurea: results of the Pakistani cohort of the VIRTUE study.
Topics: Adamantane; Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Middle Aged; Nitriles; Pakistan; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2014 |
[Safety and efficacy of Vildagliptin in real life Chilean diabetic patients].
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Body Mass Index; Chile; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Retrospective Studies; Vildagliptin | 2015 |
Gliptins: bullous pemphigoid.
Topics: Adamantane; Aged; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Male; Nitriles; Pemphigoid, Bullous; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2015 |
Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Asia; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Young Adult | 2016 |
Dipeptidyl peptidase 4 inhibitor improves brain insulin sensitivity, but fails to prevent cognitive impairment in orchiectomy obese rats.
Topics: Adamantane; Animals; Brain; Cognition; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Insulin Resistance; Male; Maze Learning; Mitochondria; Neuronal Plasticity; Nitriles; Obesity; Orchiectomy; Pyrrolidines; Rats; Rats, Wistar; Vildagliptin | 2015 |
Important species differences regarding lymph contribution to gut hormone responses.
Topics: Adamantane; Animals; Dipeptidyl Peptidase 4; Glucagon-Like Peptide 1; Intestinal Mucosa; Lymph; Nitriles; Pyrrolidines; Species Specificity; Swine; Vildagliptin | 2015 |
Regulation of Pancreatic β Cell Mass by Cross-Interaction between CCAAT Enhancer Binding Protein β Induced by Endoplasmic Reticulum Stress and AMP-Activated Protein Kinase Activity.
Topics: Adamantane; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; CCAAT-Enhancer-Binding Protein-beta; Cell Line; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; Gene Expression Regulation; Glucose Tolerance Test; Hypoglycemic Agents; Insulin-Secreting Cells; Islets of Langerhans; Metformin; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nitriles; Phosphorylation; Pyrrolidines; Ribonucleotides; Vildagliptin | 2015 |
DPP-4 Inhibitor Reduces Central Blood Pressure in a Diabetic and Hypertensive Patient: A Case Report.
Topics: Adamantane; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypertension; Hypoglycemic Agents; Middle Aged; Nitriles; Pyrrolidines; Vascular Stiffness; Vildagliptin | 2015 |
Amelioration of cyclosporine induced nephrotoxicity by dipeptidyl peptidase inhibitor vildagliptin.
Topics: Adamantane; Animals; bcl-2-Associated X Protein; Blood Urea Nitrogen; Creatinine; Cyclosporine; Dipeptidyl-Peptidase IV Inhibitors; Glutathione; Immunosuppressive Agents; Kidney; Kidney Diseases; L-Lactate Dehydrogenase; Lipid Peroxidation; Male; Nitriles; Protective Agents; Proto-Oncogene Proteins c-bcl-2; Pyrrolidines; Rats, Wistar; Serum Albumin; Superoxide Dismutase; Vildagliptin | 2015 |
Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.
Topics: Adamantane; Aged; Aged, 80 and over; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Emergency Service, Hospital; Female; France; Hospitalization; Humans; Hypoglycemia; Insurance, Health; Male; Middle Aged; Nitriles; Pyrrolidines; Regression Analysis; Sulfonylurea Compounds; Vildagliptin | 2015 |
Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice.
Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Dipeptidyl Peptidase 4; Humans; In Situ Nick-End Labeling; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Nitriles; Pyrrolidines; Vildagliptin; Xenograft Model Antitumor Assays | 2015 |
Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats.
Topics: Adamantane; Animals; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Chloroquine; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Administration Schedule; Injections, Subcutaneous; Male; Microtubule-Associated Proteins; Myocardial Infarction; Myocardium; Nitriles; Proto-Oncogene Proteins c-bcl-2; Pyrrolidines; Rats, Inbred OLETF; Signal Transduction; Time Factors; Ventricular Function, Left; Vildagliptin | 2015 |
Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus.
Topics: Adamantane; Adult; Apelin; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Time Factors; Treatment Outcome; Up-Regulation; Vildagliptin | 2015 |
Potential effects of vildagliptin on biomarkers associated with prothrombosis in diabetes mellitus.
Topics: Adamantane; Administration, Oral; Animals; Biomarkers; Diabetes Mellitus, Experimental; Disease Progression; Drug Therapy, Combination; Fibrinogen; Hypoglycemic Agents; Male; Nitriles; Pioglitazone; Platelet Count; Pyrrolidines; Rats; Rats, Sprague-Dawley; Streptozocin; Thiazolidinediones; Thrombosis; Vildagliptin | 2015 |
Neuroprotective effect of selective DPP-4 inhibitor in experimental vascular dementia.
Topics: Adamantane; Animals; Attention; Blood-Brain Barrier; Brain; Capillary Permeability; Dementia, Vascular; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Executive Function; Male; Maze Learning; Neuroprotective Agents; Nitriles; Pancreatectomy; Pyrrolidines; Rats, Wistar; Treatment Outcome; Vildagliptin | 2015 |
[The perception gap between clinical trials and clinical practice].
Topics: Adamantane; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Diabetes Mellitus; Humans; Male; Nitriles; Olanzapine; Pyrrolidines; Schizophrenia; Vildagliptin | 2015 |
Dipeptidyl peptidase-4 inhibitors and the ischemic heart: Additional benefits beyond glycemic control.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Ischemia; Nitriles; Obesity; Oxidative Stress; Pyrrolidines; Rats; Sitagliptin Phosphate; Ventricular Function, Left; Vildagliptin | 2016 |
Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles - Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin.
Topics: Adamantane; Administration, Intravenous; Administration, Oral; Animals; Biphenyl Compounds; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Haplorhini; Humans; Nitriles; Piperidines; Prospective Studies; Pyridines; Pyrrolidines; Quinolizines; Rats; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2015 |
Favorable effects of vildagliptin on metabolic and cognitive dysfunctions in streptozotocin-induced diabetic rats.
Topics: Adamantane; Animals; Behavior, Animal; Body Weight; Brain; Brain-Derived Neurotrophic Factor; Cognition; Diabetes Mellitus, Experimental; Male; Neuroprotective Agents; Nitriles; Oxidative Stress; Pyrrolidines; Rats; Rats, Sprague-Dawley; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Vildagliptin | 2015 |
The protective effect of vildagliptin in chronic experimental cyclosporine A-induced hepatotoxicity.
Topics: Adamantane; Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Catalase; Chemical and Drug Induced Liver Injury; Cyclosporine; Glutathione; Glutathione Peroxidase; Lipid Peroxidation; Liver; Male; Nitriles; Oxidative Stress; Protective Agents; Pyrrolidines; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances; Vildagliptin | 2016 |
Identification, isolation and characterization of potential process-related impurity and its degradation product in vildagliptin.
Topics: Adamantane; Chromatography, High Pressure Liquid; Dipeptidyl-Peptidase IV Inhibitors; Drug Contamination; Molecular Structure; Nitriles; Pyrrolidines; Spectrometry, Mass, Electrospray Ionization; Technology, Pharmaceutical; Vildagliptin | 2016 |
CD26 costimulatory blockade improves lung allograft rejection and is associated with enhanced interleukin-10 expression.
Topics: Adamantane; Allografts; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; DNA; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation; Graft Rejection; Immunohistochemistry; Interleukin-10; Lung Transplantation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nitriles; Pyrrolidines; Vildagliptin | 2016 |
Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate.
Topics: Adamantane; Animals; Cells, Cultured; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Inflammation; Lipopolysaccharides; Mannosephosphates; Mice; Mice, Inbred C57BL; NF-kappa B; Nitric Oxide Synthase Type II; Nitriles; Pyrrolidines; RNA, Messenger; Toll-Like Receptors; Vildagliptin | 2016 |
Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
Topics: Adamantane; Aged; Asian People; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Female; Glycated Hemoglobin; Health Status Disparities; Humans; Japan; Male; Middle Aged; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Treatment Outcome; Vildagliptin; White People | 2016 |
Development and validation of a cyclodextrin-modified capillary electrophoresis method for the enantiomeric separation of vildagliptin enantiomers.
Topics: Adamantane; Cyclodextrins; Diabetes Mellitus, Type 2; Electrophoresis, Capillary; Hydrogen-Ion Concentration; Hypoglycemic Agents; Limit of Detection; Nitriles; Pyrrolidines; Reproducibility of Results; Stereoisomerism; Temperature; Vildagliptin | 2016 |
Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction.
Topics: Adamantane; Animals; Cardiotonic Agents; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enalapril; Heart Rate; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Myocardial Infarction; Nitriles; Oxidative Stress; Pyrrolidines; Rats; Rats, Wistar; Ventricular Remodeling; Vildagliptin | 2016 |
Population pharmacokinetic modeling and noncompartmental analysis demonstrated bioequivalence between metformin component of metformin/vildagliptin fixed-dose combination products and metformin immediate-release tablet sourced from various countries.
Topics: Adamantane; Adolescent; Adult; Drug Combinations; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Biological; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Retrospective Studies; Tablets; Therapeutic Equivalency; Vildagliptin; Young Adult | 2016 |
Urinary metabolomic profiling in mice with diet-induced obesity and type 2 diabetes mellitus after treatment with metformin, vildagliptin and their combination.
Topics: Adamantane; Animals; beta-Alanine; Diabetes Mellitus, Type 2; Diet; Glucose Tolerance Test; Hypoglycemic Agents; Male; Metabolomics; Metformin; Mice; Mice, Inbred C57BL; Nitriles; Obesity; Pyridones; Pyrrolidines; Vildagliptin | 2016 |
Switching from subcutaneous insulin injection to oral vildagliptin administration in hemodialysis patients with type 2 diabetes: a pilot study.
Topics: Adamantane; Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Substitution; Feasibility Studies; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Insulin; Male; Middle Aged; Nitriles; Patient Safety; Patient Selection; Pilot Projects; Pyrrolidines; Renal Dialysis; ROC Curve; Treatment Outcome; Vildagliptin | 2016 |
MicroRNA expression in the vildagliptin-treated two- and three-dimensional HepG2 cells.
Topics: Adamantane; Animals; Cell Culture Techniques; Dipeptidyl-Peptidase IV Inhibitors; Hep G2 Cells; Humans; Hypoglycemic Agents; Liver; Male; Mice, Inbred C57BL; MicroRNAs; Nitriles; Pyrrolidines; Vildagliptin | 2016 |
Effect of vildagliptin and pravastatin combination on cholesterol efflux in adipocytes.
Topics: 3T3-L1 Cells; Adamantane; Adipocytes; Animals; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; Cholesterol; Cholesterol, HDL; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Liver X Receptors; Mice; Nitriles; Pravastatin; Pyrrolidines; Vildagliptin | 2016 |
Low-carbohydrate diet combined with SGLT2 inhibitor for refractory hyperglycemia caused by insulin antibodies.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Restricted; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin Antibodies; Insulin Resistance; Male; Metformin; Nitriles; Pyrrolidines; Sodium-Glucose Transporter 2 Inhibitors; Vildagliptin | 2016 |
Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats.
Topics: Adamantane; Animals; Cardiotonic Agents; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Estrogens; Female; Heart Rate; Hypoglycemic Agents; Insulin Resistance; Menopause, Premature; Metformin; Mitochondria, Heart; Nitriles; Obesity; Ovariectomy; Oxidative Stress; Pyrrolidines; Rats; Rats, Wistar; Vildagliptin | 2016 |
Effectiveness of vildagliptin versus other oral antidiabetes drugs as add-on to sulphonylurea monotherapy: Post hoc analysis from the EDGE study.
Topics: Adamantane; Administration, Oral; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; India; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nitriles; Odds Ratio; Prospective Studies; Pyrrolidines; Risk Factors; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Vildagliptin; Weight Gain | 2016 |
Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy.
Topics: Adamantane; Adult; Age Factors; Aged; Asia, Eastern; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Latin America; Male; Metformin; Middle Aged; Middle East; Nitriles; Pyrrolidines; Sex Factors; Treatment Outcome; Vildagliptin | 2016 |
No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
Topics: Adamantane; Aged; Cohort Studies; Diabetes Mellitus; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Nitriles; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Taiwan; Treatment Outcome; Vildagliptin | 2016 |
A case of bullous pemphigoid ınduced by vildagliptin.
Topics: Adamantane; Administration, Cutaneous; Clobetasol; Complement C3; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Eruptions; Female; Fluorescent Antibody Technique; Gliclazide; Glucocorticoids; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Nitriles; Pemphigoid, Bullous; Pyrrolidines; Skin; Vildagliptin; Withholding Treatment | 2017 |
Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
Topics: Adamantane; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; General Practice; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Nitriles; Piperidines; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Uracil; Vildagliptin | 2016 |
Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Kidney Failure, Chronic; Linagliptin; Lipids; Male; Middle Aged; Nitriles; Peritoneal Dialysis; Pyrrolidines; Renal Dialysis; Retrospective Studies; Sitagliptin Phosphate; Treatment Outcome; Vildagliptin | 2016 |
Vildagliptin-induced acute lung injury: a case report.
Topics: Acute Lung Injury; Adamantane; Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin | 2016 |
Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats.
Topics: Adamantane; Animals; Blood Glucose; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hypoglycemic Agents; Inflammation; Insulin; Kidney; Liver; Male; Nitriles; Oxidative Stress; Pancreas; Pioglitazone; Pyrrolidines; Rats; Rats, Wistar; Thiazolidinediones; Urea; Vildagliptin | 2016 |
Pattern of Onset and Risk Factors for Peripheral Oedema During Vildagliptin Use: Analysis from the Vildagliptin Prescription-Event Monitoring Study in England.
Topics: Adamantane; Aged; Cohort Studies; Edema; England; Female; Humans; Male; Middle Aged; Nitriles; Prescription Drug Monitoring Programs; Pyrrolidines; Sex Factors; Vildagliptin | 2016 |
Vildagliptin reduces cardiac ischemic-reperfusion injury in obese orchiectomized rats.
Topics: Adamantane; Androgens; Animals; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Heart; Heart Rate; Insulin Resistance; Male; Mitochondria, Heart; Myocardial Reperfusion Injury; Nitriles; Obesity; Orchiectomy; Pyrrolidines; Rats; Rats, Wistar; Testosterone; Ventricular Function, Left; Vildagliptin | 2016 |
Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.
Topics: Acinar Cells; Adamantane; Adenocarcinoma; Adult; Aged; Carcinoma in Situ; Case-Control Studies; Cystadenoma; Diabetes Mellitus, Type 2; Digestive System Surgical Procedures; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Secreting Cells; Humans; Incretins; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Middle Aged; Neuroendocrine Tumors; Nitriles; Organ Size; Pancreas; Pancreas, Exocrine; Pancreatic Neoplasms; Pancreatitis, Chronic; Peptides; Pyrrolidines; Sitagliptin Phosphate; Tissue Donors; Venoms; Vildagliptin | 2016 |
Blood pressure and fasting lipid changes after 24 weeks' treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus.
Topics: Adamantane; Biomarkers; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Humans; Linear Models; Lipids; Male; Middle Aged; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Treatment Outcome; Vildagliptin; Weight Loss | 2016 |
The effect of vildagliptin relative to sulfonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan in the Middle East: the VIRTUE study.
Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemic Agents; Islam; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2017 |
Acute Toxicity of Vildagliptin.
Topics: Adamantane; Administration, Oral; Animals; Dipeptidyl-Peptidase IV Inhibitors; Edema; Female; Macaca fascicularis; Male; Nitriles; Pyrrolidines; Species Specificity; Toxicity Tests, Acute; Vasoconstriction; Vildagliptin | 2017 |
Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human hepatoma HepG2 and leukemia HL-60 cells.
Topics: Adamantane; Animals; Calgranulin A; Calgranulin B; Cell Line, Tumor; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression Profiling; Hep G2 Cells; Hepatocytes; HL-60 Cells; Humans; Leukocytes; Mice; Microarray Analysis; Nitriles; Pyrrolidines; Vildagliptin | 2016 |
Vildagliptin and caloric restriction for cardioprotection in pre-diabetic rats.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Caloric Restriction; Cardiotonic Agents; Diet, High-Fat; Fibroblast Growth Factors; Heart Rate; Insulin Resistance; Intra-Abdominal Fat; Male; Mitochondria, Heart; Nitriles; Oxidative Stress; Prediabetic State; Pyrrolidines; Rats; Rats, Wistar; Ventricular Function, Left; Vildagliptin | 2017 |
Hepatic Dipeptidyl Peptidase-4 Controls Pharmacokinetics of Vildagliptin In Vivo.
Topics: Adamantane; Animals; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hydrolysis; Liver; Male; Metabolic Networks and Pathways; Mice; Mice, Inbred C57BL; Nitriles; Pyrrolidines; Tissue Distribution; Vildagliptin | 2017 |
Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies.
Topics: Adamantane; Adult; Aged; Asian People; Blood Glucose; China; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Ethnicity; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Insulin; Japan; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Racial Groups; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin; White People | 2017 |
Evaluation of drug efficacy of DPP-4 inhibitors based on theoretical analysis with pharmacokinetics and pharmacodynamics.
Topics: Adamantane; Algorithms; Area Under Curve; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrrolidines; Treatment Outcome; Uracil; Vildagliptin | 2017 |
Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats.
Topics: Adamantane; Animals; Biomarkers; Bone Density; Bone Resorption; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Male; Nitriles; Pioglitazone; Pyrrolidines; Rats; Rats, Zucker; Tartrate-Resistant Acid Phosphatase; Thiazolidinediones; Vildagliptin | 2016 |
Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
Topics: Adamantane; Adult; Aged; Biomarkers, Pharmacological; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Health Status Indicators; Humans; Linagliptin; Male; Middle Aged; Nitriles; Predictive Value of Tests; Prognosis; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Treatment Outcome; Vildagliptin | 2017 |
Effects of Vildagliptin and Metformin on Blood Pressure and Heart Rate Responses to Small Intestinal Glucose in Type 2 Diabetes.
Topics: Adamantane; Aged; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucose; Heart Rate; Humans; Hypoglycemic Agents; Intestine, Small; Male; Metformin; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin | 2017 |
Profiling Proteinic Changes Induced by Vildagliptin Treatment in a Mouse Lung Transplantation Model: The Role of Kininogen-1.
Topics: Adamantane; Animals; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Down-Regulation; Immunohistochemistry; Kininogens; Lung; Lung Transplantation; Male; Mice; Nitriles; Peroxidase; Pyrrolidines; Up-Regulation; Vildagliptin | 2017 |
Trigonelline and vildagliptin antidiabetic effect: improvement of insulin signalling pathway.
Topics: Adamantane; Alkaloids; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipids; Male; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Receptor, Insulin; Signal Transduction; Vildagliptin | 2017 |
DPP-4 Inhibitor and Estrogen Share Similar Efficacy Against Cardiac Ischemic-Reperfusion Injury in Obese-Insulin Resistant and Estrogen-Deprived Female Rats.
Topics: Adamantane; Animals; Apoptosis; Blood Glucose; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Estradiol; Fasting; Female; Heart Rate; Insulin Resistance; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Nitriles; Obesity; Ovariectomy; Pyrrolidines; Rats; Rats, Wistar; Stroke Volume; Ventricular Function, Left; Vildagliptin | 2017 |
Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study.
Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Monitoring; Drug Therapy, Combination; Egypt; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin | 2017 |
Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi-database, non-interventional post-authorization safety study.
Topics: Adamantane; Adult; Aged; Cardiotoxicity; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Europe; Female; Humans; Male; Middle Aged; Nitriles; Pyrrolidines; Retrospective Studies; Vildagliptin | 2017 |
Comparisons of cardioprotective efficacy between fibroblast growth factor 21 and dipeptidyl peptidase-4 inhibitor in prediabetic rats.
Topics: Adamantane; Animals; Cardiotonic Agents; Diabetic Cardiomyopathies; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Fibroblast Growth Factors; Gene Expression Regulation; Heart Rate; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mitochondria, Heart; Nitriles; Obesity; Prediabetic State; Pyrrolidines; Rats; Rats, Wistar; Recombinant Proteins; Tumor Necrosis Factor-alpha; Ventricular Dysfunction, Left; Vildagliptin | 2017 |
Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Retrospective Studies; Treatment Outcome; Vildagliptin | 2018 |
Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury.
Topics: Adamantane; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Kidney; Linagliptin; Male; Molecular Structure; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Reperfusion Injury; Sitagliptin Phosphate; Structure-Activity Relationship; Vildagliptin | 2017 |
GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in βIRKO mice.
Topics: Adamantane; Animals; Cell Proliferation; Cyclin A; Cyclin D; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Insulin; Insulin-Secreting Cells; Mice; Mice, Knockout; Nitriles; Peptides; Phosphorylation; Pyrrolidines; Receptor, Insulin; Signal Transduction; Venoms; Vildagliptin | 2017 |
Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study. Curr
Topics: Adamantane; Egypt; Humans; Metformin; Non-alcoholic Fatty Liver Disease; Uric Acid; Vildagliptin | 2017 |
Mast Cell and M1 Macrophage Infiltration and Local Pro-Inflammatory Factors Were Attenuated with Incretin-Based Therapies in Obesity-Related Glomerulopathy.
Topics: Adamantane; Albuminuria; Animals; Creatinine; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucose Tolerance Test; Incretins; Inflammation; Interleukin-6; Kidney Diseases; Kidney Glomerulus; Liraglutide; Macrophages; Male; Mast Cells; Nitriles; Obesity; Pyrrolidines; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; Vildagliptin | 2017 |
SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
Topics: Adamantane; Animals; Anti-Inflammatory Agents; Apoptosis; Benzhydryl Compounds; Brain; Cognition Disorders; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Insulin; Insulin Resistance; Long-Term Potentiation; Male; Malondialdehyde; Maze Learning; Membrane Potential, Mitochondrial; Memory; Mitochondria; Neuroprotective Agents; Nitriles; Obesity; Oxidative Stress; Pyrrolidines; Rats, Wistar; Reactive Oxygen Species; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vildagliptin | 2017 |
The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity.
Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Cell Membrane; Cell Nucleus; Colorectal Neoplasms; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Injections, Subcutaneous; Iron; Lipid Peroxidation; Mice; Mice, Nude; Nitriles; Piperazines; Pyrrolidines; RNA, Small Interfering; Signal Transduction; Tumor Suppressor Protein p53; Vildagliptin; Xenograft Model Antitumor Assays | 2017 |
Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients.
Topics: Adamantane; Adipose Tissue; Adult; Aged; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Vildagliptin | 2017 |
Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.
Topics: Adamantane; Aged; Aged, 80 and over; Autoantibodies; Autoantigens; Collagen Type XVII; Dipeptidyl-Peptidase IV Inhibitors; Epitopes; Female; Humans; Immunoglobulin A; Immunoglobulin E; Immunoglobulin G; Linagliptin; Male; Membrane Glycoproteins; Middle Aged; Nitriles; Non-Fibrillar Collagens; Pemphigoid, Bullous; Piperidines; Pyrrolidines; Sitagliptin Phosphate; Uracil; Vildagliptin | 2018 |
Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph
Topics: Adamantane; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Coculture Techniques; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Fibroblasts; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplasm Proteins; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Pyrrolidines; Tumor Cells, Cultured; Vildagliptin; Xenograft Model Antitumor Assays | 2018 |
Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats.
Topics: Adamantane; Administration, Oral; Animals; Blood Glucose; Butyrates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Insulin Resistance; Interleukin-6; Male; Nitriles; Pyrrolidines; Random Allocation; Rats, Sprague-Dawley; RNA, Ribosomal, 16S; Vildagliptin | 2017 |
Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition.
Topics: Adamantane; Animals; Dipeptidyl-Peptidase IV Inhibitors; Epithelial-Mesenchymal Transition; Lipopolysaccharides; Lung Injury; Male; Mice; Mice, Inbred C57BL; Nitriles; Pulmonary Fibrosis; Pyrrolidines; Vildagliptin | 2017 |
Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study).
Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Chi-Square Distribution; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Logistic Models; Male; Metformin; Middle Aged; Multivariate Analysis; Nitriles; Pyrrolidines; Republic of Korea; Retrospective Studies; Time Factors; Treatment Outcome; Vildagliptin | 2017 |
Dipeptidyl peptidase-4 inhibitor enhances restoration of salivary glands impaired by obese-insulin resistance.
Topics: Adamantane; Animals; Apoptosis; Blotting, Western; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Inflammation; Insulin Resistance; Male; Mitochondria; Nitriles; Obesity; Oxidative Stress; Pyrrolidines; Rats; Rats, Wistar; Salivary Glands; Vildagliptin | 2018 |
Vildagliptin-induced acute pancreatitis without enzyme elevation.
Topics: Abdominal Pain; Acute Disease; Adamantane; Aged; Amylases; Diabetes Mellitus, Type 2; Diagnosis, Differential; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Lipase; Male; Middle Aged; Nitriles; Pancreatitis; Pyrrolidines; Vildagliptin | 2017 |
Vildagliptin loaded triangular DNA nanospheres coated with eudragit for oral delivery and better glycemic control in type 2 diabetes mellitus.
Topics: Adamantane; Administration, Oral; Animals; Blood Glucose; Crystallization; Delayed-Action Preparations; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; DNA; Drug Carriers; Drug Delivery Systems; Drug Liberation; Hypoglycemic Agents; Male; Mice; Nanospheres; Nanotechnology; Nitriles; Particle Size; Polymethacrylic Acids; Pyrrolidines; Vildagliptin | 2018 |
Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice.
Topics: 3T3-L1 Cells; Adamantane; Adipocytes; Adipose Tissue, White; Animals; Blood Glucose; Collagen; Diet, High-Fat; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Extracellular Matrix; Fibrosis; Hypolipidemic Agents; Leptin; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Neuropeptide Y; Nitriles; Obesity; Pyrrolidines; Receptors, Neuropeptide Y; RNA Interference; RNA, Small Interfering; Transforming Growth Factor beta1; Vildagliptin | 2018 |
Vildagliptin prevents cognitive deficits and neuronal apoptosis in a rat model of Alzheimer's disease.
Topics: Adamantane; Alzheimer Disease; Amyloid beta-Peptides; Animals; bcl-2-Associated X Protein; Caspase 3; Cognitive Dysfunction; Disease Models, Animal; Disks Large Homolog 4 Protein; Gene Expression Regulation; Glycogen Synthase Kinase 3 beta; Hippocampus; Injections, Intraventricular; Male; Maze Learning; Neurons; Neuroprotective Agents; Nitriles; Nootropic Agents; Peptide Fragments; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrrolidines; Rats; Rats, Sprague-Dawley; Signal Transduction; Synaptophysin; tau Proteins; Vildagliptin | 2018 |
Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.
Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Monitoring; Exenatide; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Ligands; Liraglutide; Models, Molecular; Molecular Targeted Therapy; Nitriles; Peptides; Piperidines; Pyrrolidines; Reproducibility of Results; Sitagliptin Phosphate; Uracil; Venoms; Vildagliptin | 2018 |
Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin | 2018 |
Anti-diabetic Phenolic Compounds of Black Carrot (Daucus carota Subspecies sativus var. atrorubens Alef.) Inhibit Enzymes of Glucose Metabolism: An in silico and in vitro Validation.
Topics: Acarbose; Adamantane; alpha-Amylases; Anthocyanins; Daucus carota; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Hydrogen Bonding; Hypoglycemic Agents; Molecular Docking Simulation; Nitriles; Phenols; Pyrrolidines; Vildagliptin | 2018 |
Vildagliptin/pioglitazone combination improved the overall glycemic control in type I diabetic rats.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucagon; Glutathione; Glycated Hemoglobin; Insulin; Male; Malondialdehyde; Nitric Oxide; Nitriles; Pancreas; Pioglitazone; Pyrrolidines; Rats, Sprague-Dawley; Streptozocin; Superoxide Dismutase; Thiazolidinediones; Vildagliptin | 2018 |
Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
Topics: Adamantane; Aged; Aged, 80 and over; Autoantigens; Collagen Type XVII; Dipeptidyl-Peptidase IV Inhibitors; Dystonin; Female; Humans; Immunoglobulin G; Linagliptin; Male; Nitriles; Non-Fibrillar Collagens; Pemphigoid, Bullous; Phenotype; Pyrrolidines; Sitagliptin Phosphate; Vildagliptin | 2018 |
FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats.
Topics: Adamantane; Animals; Apoptosis; Cognitive Dysfunction; Dipeptidyl-Peptidase IV Inhibitors; Fibroblast Growth Factors; Hippocampus; Humans; Insulin Resistance; Male; Malondialdehyde; Mitochondria; Neuronal Plasticity; Nitriles; Obesity; Oxidative Stress; Pyrrolidines; Rats, Wistar; Signal Transduction; Vildagliptin | 2018 |
A Possible Mechanism: Vildagliptin Prevents Aortic Dysfunction through Paraoxonase and Angiopoietin-Like 3.
Topics: Adamantane; Angiopoietin-like Proteins; Angiopoietins; Animals; Aryldialkylphosphatase; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Male; Nitriles; Pyrrolidines; Rats; Rats, Sprague-Dawley; Vildagliptin | 2018 |
Neuroprotective effect of vildagliptin against cerebral ischemia in rats.
Topics: Adamantane; Animals; Caspase 3; Dipeptidyl-Peptidase IV Inhibitors; Glutathione; Infarction, Middle Cerebral Artery; Locomotion; Male; Malondialdehyde; Neuroprotective Agents; Nitriles; Phosphatidylinositol 3-Kinases; Pyrrolidines; Rats, Wistar; TOR Serine-Threonine Kinases; Vildagliptin | 2018 |
Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings
.
Topics: Adamantane; Adult; Age Factors; Aged; Biomarkers; Blood Glucose; Clinical Decision-Making; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Germany; Humans; Male; Middle Aged; Patient Selection; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Sex Factors; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Vildagliptin | 2018 |
Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
Topics: Adamantane; Adult; Age Factors; Aged; Case-Control Studies; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Incidence; Linagliptin; Male; Middle Aged; Pemphigoid, Bullous; Piperidines; Risk Factors; Sitagliptin Phosphate; Taiwan; Uracil; Vildagliptin; Young Adult | 2020 |
Saxagliptin and vildagliptin lowered albuminuria in patients with diabetes and hypertension independent on glycaemic control.
Topics: Adamantane; Albuminuria; Animals; Diabetes Mellitus, Type 2; Dipeptides; Glycemic Control; Humans; Hypertension; Rats; Vildagliptin | 2021 |
A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment.
Topics: Acarbose; Adamantane; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Male; Middle Aged; Prognosis; Vildagliptin | 2021 |
Vitamin D3 potentiates the nephroprotective effects of vildagliptin-metformin combination in a rat model of metabolic syndrome.
Topics: Adamantane; Animals; Cholecalciferol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Vildagliptin | 2022 |
Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China.
Topics: Adamantane; China; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Humans; Linagliptin; Metformin; Middle Aged; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil; Vildagliptin | 2021 |
Efficacy of vildagliptin on 10-year cardiovascular risk reduction in Thai patients with type 2 diabetes mellitus: A real-world observational study.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Nitriles; Risk Factors; Thailand; Treatment Outcome; Vildagliptin | 2022 |
ZD-2, a novel DPP4 inhibitor, protects islet β-cell and improves glycemic control in high-fat-diet-induced obese mice.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Glycemic Control; Hormones; Hypoglycemic Agents; Mice; Mice, Obese; Nitriles; Pyrrolidines; Vildagliptin | 2022 |
Variation in open access vildagliptin use in Waikato patients with type 2 diabetes.
Topics: Access to Information; Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; New Zealand; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2022 |